0001437749-18-009379.txt : 20180510 0001437749-18-009379.hdr.sgml : 20180510 20180510132159 ACCESSION NUMBER: 0001437749-18-009379 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180510 DATE AS OF CHANGE: 20180510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioCardia, Inc. CENTRAL INDEX KEY: 0000925741 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 232753988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21419 FILM NUMBER: 18821570 BUSINESS ADDRESS: STREET 1: 125 SHOREWAY ROAD STREET 2: SUITE B CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-226-0123 MAIL ADDRESS: STREET 1: 125 SHOREWAY ROAD STREET 2: SUITE B CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Tiger X Medical, Inc. DATE OF NAME CHANGE: 20110616 FORMER COMPANY: FORMER CONFORMED NAME: Cardo Medical, Inc. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: CLICKNSETTLE COM INC DATE OF NAME CHANGE: 20000823 10-Q 1 bcda20180331_10q.htm FORM 10-Q bcda20180331_10q.htm
 

 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 


 

FORM 10-Q

 


 

 (Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2018

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 0-21419

 

 


 

BioCardia, Inc.

(Exact name of registrant as specified in its charter)

 


 

 

Delaware

 

23-2753988

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

125 Shoreway Road, Suite B 

San Carlos, California 94070

(Address of principal executive offices including zip code)

 

(650) 226-0120

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 


 

1

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐  

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

  

  

  

  

Non-accelerated filer

 

☐  (Do not check if a smaller reporting company)

  

Smaller reporting company

 

             
        Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

There were 38,241,244 shares of the registrant’s Common Stock issued and outstanding as of May 7, 2018.

 

2

 
 
 

  

Part I.   FINANCIAL INFORMATION

 

4

 

 

 

 

 

Item 1.

  

Unaudited Condensed Consolidated Financial Statements

  

  4

  

  

Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017

  

4

  

  

Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017

  

5

  

  

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2018 and 2017

  

6

  

  

Notes to Unaudited Condensed Consolidated Financial Statements

  

7

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

14

Item 3.

  

Quantitative and Qualitative Disclosures About Market Risk

  

20

Item 4.

  

Controls and Procedures

  

 20

 

 

 

 

 

Part II.  OTHER INFORMATION

 

21

 

 

 

Item 1.

  

Legal Proceedings

  

21

Item 1A.

  

Risk Factors

  

  21

Item 2.

  

Unregistered Sales of Equity Securities and Use of Proceeds

  

21

Item 3.

  

Defaults Upon Senior Securities

  

 21

Item 4.

  

Mine Safety Disclosures

  

 21

Item 5.

  

Other Information

  

 21

Item 6.

  

Exhibits

  

21

 

 

 

 

 

SIGNATURES

 

22

EXHIBIT INDEX

 

23

 

 

 

FORWARD-LOOKING INFORMATION

 

This Quarterly Report on Form 10-Q, or report, contains forward-looking statements within the meaning of the U.S. federal securities laws that involve risks and uncertainties. Certain statements contained in this report are not purely historical including, without limitation, statements regarding our expectations, beliefs, intentions, anticipations, commitments or strategies regarding the future that are forward-looking. These statements include those discussed in Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, including “Critical Accounting Policies and Estimates,” “Results of Operations,” “Liquidity and Capital Resources,” and “Future Funding Requirements,” and elsewhere in this report.

 

In this report, the words “may,” “could,” “would,” “might,” “will,” “should,” “plan,” “ forecast,” “anticipate,” “believe,” “expect,” “intend,” “estimate,” “predict,” “potential,” “continue,” “future,” “moving toward” or the negative of these terms or other similar expressions also identify forward-looking statements. Our actual results could differ materially from those forward-looking statements contained in this report as a result of a number of risk factors including, but not limited to, those listed in our Annual Report on Form 10-K and elsewhere in this report. You should carefully consider these risks, in addition to the other information in this report and in our other filings with the SEC. All forward-looking statements and reasons why results may differ included in this report are made as of the date of this report, and we undertake no obligation to update any such forward-looking statement or reason why such results might differ after the date of this Quarterly Report on Form 10-Q, except as required by law.

 

3

 

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

BIOCARDIA, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

 

 

 

March 31,
2018

   

December 31,
2017

 
   

(unaudited)

         
Assets                
                 

Current assets:

               

Cash and cash equivalents

  $ 9,653     $ 12,689  

Accounts receivable, net of allowance for doubtful accounts of $6 at March 31, 2018 and December 31, 2017, respectively

    127       95  

Inventory

    148       191  

Prepaid expenses

    277       340  

Total current assets

    10,205       13,315  

Property and equipment, net

    152       169  

Other assets

    54       54  

Total assets

  $ 10,411     $ 13,538  

Liabilities and Stockholders’ Equity

               

Current liabilities:

               

Accounts payable

  $ 738     $ 902  

Accrued expenses and other current liabilities

    1,323       1,263  

Deferred revenue

    60       167  

Total current liabilities

    2,121       2,332  

Deferred rent

    83       81  

Total liabilities

    2,204       2,413  

Stockholders’ equity:

               

Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2018 and December 31, 2017

           

Common stock, $0.001 par value, 100,000,000 shares authorized as of March 31, 2018 and December 31, 2017 respectively; 38,241,244 and 38,218,660 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively

    38       38  

Additional paid-in capital

    84,157       83,537  

Accumulated deficit

    (75,988 )     (72,450 )

Total stockholders’ equity

    8,207       11,125  

Total liabilities and stockholders’ equity

  $ 10,411     $ 13,538  

 

See accompanying notes to condensed consolidated financial statements.

 

4

 

        

 

BIOCARDIA, INC.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(unaudited)

  

   

Three months ended March 31,

 
   

2018

   

2017

 

Revenue:

               

Net product revenue

  $ 82     $ 109  

Collaboration agreement revenue

    117       28  

Total revenue

    199       137  

Costs and expenses:

               

Cost of goods sold

    157       175  

Research and development

    1,955       1,033  

Selling, general and administrative

    1,707       1,804  

Total costs and expenses

    3,819       3,012  

Operating loss

    (3,620 )     (2,875 )

Other income (expense):

               

Interest income

    36        

Other expense, net

          (1 )

Total other income (expense), net

    36       (1 )

Net loss

  $ (3,584 )   $ (2,876 )
                 

Net loss per share, basic and diluted

  $ (0.09 )   $ (0.08 )
                 

Weighted-average shares used in computing net loss per share, basic and diluted

    38,236,056       38,137,881  

 

See accompanying notes to condensed consolidated financial statements.

  

5

 

 

 

BIOCARDIA, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(unaudited)

  

   

Three months ended March 31,

 
   

2018

   

2017

 

Operating activities:

               

Net loss

  $ (3,584 )   $ (2,876 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    22       13  

Share-based compensation

    615       622  

Changes in operating assets and liabilities:

               

Accounts receivable

    (32 )     (47 )

Inventory

    43       (9 )

Prepaid expenses

    63       104  

Accounts payable

    (164 )     (249 )

Accrued liabilities

    34       157  

Deferred revenue

    (35 )     1  

Deferred rent

    2       6  

Net cash used in operating activities

    (3,036 )     (2,278 )

Investing activities:

               

Purchase of property and equipment

    (5 )     (64 )

Net used in in investing activities

    (5 )     (64 )

Financing activities:

               

Proceeds from the exercise of common stock options

    5       22  

Net cash provided by financing activities

    5       22  

Net decrease in cash and cash equivalents

    (3,036 )     (2,320 )

Cash and cash equivalents at beginning of period

    12,689       21,352  

Cash and cash equivalents at end of period

  $ 9,653     $ 19,032  
                 

Supplemental disclosure of noncash investing activity:

               

Accounts payable recognized for the purchase of equipment

  $     $ 15  

 

See accompanying notes to condensed consolidated financial statements.

 

6

 

 

 

(1)

Summary of Business and Basis of Presentation

 

 

(a)

Description of Business

     
    BioCardia, Inc., (We or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the CardiAMP cell therapy system and our second therapeutic candidate is the CardiALLO cell therapy system. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property.
     
    We have three enabling device product lines: (1) the CardiAMP cell processing system; (2) the Helix biotherapeutic delivery system, or Helix; and (3) the Morph vascular access product line, or Morph. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.

 

 

(2)

Significant Accounting Policies

 

 

(a)

Basis of Preparation

     
    The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of March 31, 2018 and for the three months ended March 31, 2018 and 2017 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position as of March 31, 2018, results of operations for the three months ended March 31, 2018 and 2017, and cash flows for the three months ended March 31, 2018 and 2017. The results for the three months ended March 31, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018 or for any other interim period or for any other future year.
     
    These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018.

 

 

(b)

Liquidity

     
    We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of $76.0 million as of March 31, 2018. Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of  $9.7 million as of March 31, 2018 are sufficient to fund the Company into the fourth quarter of 2018. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
     
   

Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP cell therapy system, and our second therapeutic candidate, the CardiALLO cell therapy system, through and beyond the fourth quarter of 2018, will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

 

7

 

 

 

(c)

Use of Estimates

 

The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.

 

 

(d)

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.

 

 

(e)

Changes to Significant Accounting Policies

 

Our significant accounting policies are described in Note 2 of the notes to the financial statements included in our Annual Report on Form 10-K filed for the year ended 2017. Apart from the adoption of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) on January 1, 2018 which led to an amended revenue policy, as described in the following paragraphs, there have been no changes to those policies.

 

Revenue Recognition

 

Net product revenue – We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.

 

Collaboration agreement revenue – Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.

 

Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.

 

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

 

 

(f)

Recently Adopted Accounting Pronouncement

 

In May 2014, the FASB issued Topic 606, which provides comprehensive guidance for revenue recognition. Topic 606 affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. 

 

8

 

 

On January 1, 2018, we adopted Topic 606 using the cumulative effect adoption method. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Topic 605. The adoption of Topic 606 did not have a material impact on our financial statements.

 

In January 2016, the FASB issued ASU No. 2016-01 (ASU 2016-01), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU 2016-01 on January 1, 2018 and the adoption did not have a material impact on our financial statements.

 

In May 2017, the FASB issued ASU No. 2017-09 Compensation – Stock Compensation (Topic 718) Scope of Modification Accounting (ASU 2017-09). The amendments in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. We adopted ASU 2017-09 effective January 1, 2018, and the adoption did not have a material impact on our financial statements.

 

 

(g)

Recently Issued Accounting Pronouncements

 

In February 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842) (ASU 2016-02), which supersedes existing guidance on accounting for leases in Leases (Topic 840) and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The Company does not plan to elect early adoption. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently assessing the future impact of this ASU on its consolidated financial statements.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not or are not believed by management to have a material impact on the Company’s financial statement presentation or disclosures.

 

 

(3)     Fair Value Measurement

 

The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three levels:

 

Level 1 – quoted prices in active markets for identical assets and liabilities

 

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

 

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

9

 

 

The following table sets forth the fair value of our financial assets measured on a recurring basis as of March 31, 2018 and December 31, 2017 and indicates the fair value hierarchy utilized to determine such fair value (in thousands).

 

   

As of March 31, 2018

 
                                 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Assets:

                               

Cash and cash equivalents

  $ 9,653     $     $     $ 9,653  

 

   

As of December 31, 2017

 
   

Level 1

   

Level 2

   

Level 3

   

Total

 

Assets:

                               

Cash and cash equivalents

  $ 12,689     $     $     $ 12,689  

 

 

 

(4)

Inventories

 

Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands):

 

   

March 31, 2018

   

December 31, 2017

 

Raw materials

  $ 78     $ 70  

Work in process

    15       92  

Finished goods

    55       29  

Total

  $ 148     $ 191  

 

Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may result in recording additional write downs for excess or expired inventory in the future. Charges to cost of goods sold for inventory write-downs, reserve adjustments, scrap, shrinkage and expired inventories totaled approximately $2,000, and $9,000 for the three months ended March 31, 2018 and 2017, respectively.

 

 

(5)

Property and Equipment, Net

 

Property and equipment, net consisted of the following (in thousands):

  

   

March 31,
2018

   

December 31,
2017

 

Computer equipment and software

  $ 110       106  

Laboratory and manufacturing equipment

    447       447  

Furniture and fixtures

    48       48  

Leasehold improvements

    326       326  

Property and equipment, gross

    931       927  

Less accumulated depreciation

    (779 )     (758 )

Property and equipment, net

  $ 152       169  

 

Depreciation expense totaled approximately $22,000 and $13,000 for the three months ended March 31, 2018 and 2017, respectively.

 

10

 

  

 

(6)

Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

  

   

March 31,
2018

   

December 31,
2017

 

Accrued expenses

  $ 579     $ 539  

Grant liability

    654       663  

Customer deposits

    90       61  

Total

  $ 1,323     $ 1,263  

 

 

(7)

Share-Based Compensation

 

The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function. No share-based compensation was capitalized during the periods presented. Share-based compensation expense for the three months ended March 31, 2018 and 2017 was recorded as follows (in thousands):

  

   

Three months ended March 31,

 
   

2018

   

2017

 

Cost of goods sold

  $ 30     $ 41  

Research and development

    197       172  

Selling, general and administrative

    388       409  

Share-based compensation expense

  $ 615     $ 622  

 

The following table summarizes the activity of stock options and related information:

 

           

Weighted

 
           

average

 
   

Number of

   

exercise

 
   

shares

   

price

 

Balance, December 31, 2017

    4,213,100     $ 2.96  

Stock options granted

    1,429,075       2.60  

Stock options exercised

    (2,488 )     1.80  

Stock options cancelled

    (20,833 )     7.56  

Balance, March 31, 2018

    5,618,854     $ 2.85  

 

The weighted average grant-date fair value of options granted during the three months ended March 31, 2018 was $1.86 per share.

 

Employee Share-Based Compensation (Stock Options)

 

During the three months ended March 31, 2018, we granted stock options to certain non-employee directors and employees to purchase 1,429,075 shares of common stock. The fair value of each option grant was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:  

 

Risk-free interest rate

    2.66%  

Volatility

    81%  

Dividend yield

 

None

 

Expected term (in years)

    6.25%  

 

Unrecognized share-based compensation for employee options granted through March 31, 2018 is approximately $6.7 million to be recognized over a remaining weighted average service period of 3.1 years.

 

11

 

 

Non-Employee Director Share-Based Compensation (RSUs)

 

The following summarizes the activity of non-vested RSUs:

  

           

Weighted

 
           

average

 
           

grant date

 
   

Number of

   

fair value

 
   

shares

   

per share

 

Balance, December 31, 2017

    97,996     $ 8.71  

RSUs granted

             

RSUs vested

    (20,444 )     11.04  

RSUs forfeited

             

Balance, March 31, 2018

    77,552     $ 8.09  

 

Unrecognized share-based compensation for employee RSUs granted through March 31, 2018 is approximately $441,000 to be recognized over a remaining weighted average service period of 1.7 years.

 

Nonemployee Share-Based Compensation

 

During the three months ended March 31, 2018, we did not grant any options to purchase shares of common stock to consultants. Options granted to consultants have been granted in exchange for consulting services to be rendered and vest over the term specified in the grant, which correlates to the period the services are rendered. We recorded approximately $45,000 and $233,000 for the three months ended March 31, 2018 and 2017, respectively, as nonemployee share-based compensation expense.

 

The Company accounts for share-based compensation arrangements with nonemployees, using the Black-Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, the Company revalues the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards for the three months ended March 31, 2018:

 

Risk-free interest rate

    2.83%  

Volatility

    80%  
Dividend yield     None  

Expected term (in years)

   8.4 - 8.8
         

 

 

(8)

Net Loss per Share

 

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to our net loss position.  

 

The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

 

   

Three months ended March 31,

 
   

2018

   

2017

 

Stock options to purchase common stock

    5,618,854       3,816,927  

Unvested restricted stock units

    77,552       61,333  

Total

    5,696,406       3,878,260  

 

12

 

 

 

(9)     Income Taxes

 

During the three months ended March 31, 2018 and 2017, there was no income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statement of operations due to the Company’s net loss and a full valuation allowance on the resulting deferred tax assets.

 

As of March 31, 2018, we retain a full valuation allowance on our deferred tax assets in all jurisdictions. The realization of our deferred tax assets depends primarily on our ability to generate future taxable income which is uncertain. We do not believe that our deferred tax assets are realizable on a more-likely-than-not basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.

 

On December 22, 2017, the Tax Cuts and Jobs Act (H.R. 1) (the Tax Act) was signed into law. The new law resulted in significant changes to the U.S. corporate income tax system. These changes included the reduction of the corporate income tax rate from a maximum rate of 35% to 21% and the elimination or reduction of certain domestic deductions and credits.

 

The 2017 provisional charge related to the Tax Act was an estimate and the measurement of net deferred tax assets is subject to further analysis and potential correlative adjustments as developing interpretations and guidance from the U.S. Treasury Department, the Internal Revenue Service, and other standard setting bodies provide additional clarifications of the provisions of the Tax Act. Updated guidance and regulations could result in changes to this provisional charge during 2018 when the analysis is complete, and, in accordance with the guidance in Staff Accounting Bulletin 118, we will continue to monitor guidance and make necessary adjustments. No measurement-period adjustments were made during the quarter ended March 31, 2018.

 

 

(10)     Related Party Transactions

 

In August 2016, we granted an option to purchase 418,977 shares of common stock, with 4-year vesting period and an exercise price of $1.80 per share, to OPKO Health, Inc. (“OPKO”) as consideration for consulting services to be provided by OPKO. We recorded $37,000 and $122,000 as share-based compensation expense related to the OPKO stock option during the three months ended March 31, 2018 and 2017, respectively. The estimated grant-date fair value of the option was $5.3 million. The term of the consulting agreement is 4 years and will be automatically renewed for successive one year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than 5% of the outstanding shares of the Company’s common stock and OPKO itself is also a beneficial owner of more than 5% of the outstanding shares of the Company’s common stock. 

 

13

 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains certain forward-looking statements that involve risk and uncertainties. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those listed in our Annual Report on Form 10-K and elsewhere in this report. Historical results are not necessarily indicative of future results.

  

 

Overview

 

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the investigational CardiAMP Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient’s own cells) for the treatment of two clinical indications: heart failure that develops after a heart attack and chronic myocardial ischemia.

 

We initiated our U.S. Food and Drug Administration, or FDA, accepted Phase III pivotal trial for CardiAMP Cell Therapy in ischemic systolic heart failure, in December 2016. The CardiAMP Heart Failure Trial is a Phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at 40 centers nationwide, which includes a 10-patient roll-in cohort. The trial’s primary endpoint is a clinical composite of six minute walk distance and major adverse cardiac and cerebrovascular events. In September 2017, the independent Data Safety Monitoring Board (DSMB) completed the pre-specified interim analysis of safety outcomes for the first 10 patients treated in the Phase III trial of its investigational CardiAMP cell therapy product. The DSMB indicated there were no significant safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. Currently 13 world class medical centers are actively enrolling in the study. Efficacy results from the primary endpoint in the open label roll in cohort are anticipated in the second half of 2018. We anticipate that trial enrollment will be completed in the first half of 2019.

 

In January 2018, the FDA approved a second investigational device exemption (IDE) for the randomized controlled pivotal trial of autologous bone marrow mononuclear cells using the CardiAMP Cell Therapy System in patients with refractory chronic myocardial ischemia for up to 343 patients at up to 40 clinical sites in the United States. This therapeutic approach uses many of the same novel aspects as the CardiAMP Heart Failure Trial and leverages our experience and investment in the heart failure trial.

 

The Department of Health & Human Services Centers for Medicare & Medicaid Services, or CMS, has designated that both the CardiAMP Heart Failure Trial and the CardiAMP Chronic Myocardial Ischemia Trial qualify for Medicare national coverage. Covered costs are anticipated to include patient screening, the CardiAMP Cell Therapy System and procedure, and clinical follow-up at one and two years after the procedure.  Private insurance plans covering 50 million insured Americans follow this CMS reimbursement policy, and are similarly anticipated to cover these costs.   

 

Our second therapeutic candidate is the CardiALLO Cell Therapy System, which utilizes bone marrow derived mesenchymal cells from a donor to treat heart failure. We anticipate submitting an Investigational New Drug (IND) application for submission to the FDA for a Phase II trial for CardiALLO Cell Therapy System for the treatment of ischemic systolic heart failure in 2018. This IND is expected to have improved Chemistry Manufacturing Controls relative to our previous co-sponsored investigations utilizing culture expanded bone marrow derived mesenchymal stem cells.

 

To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems, including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property. We have also generated modest revenues from sales of our approved products. We have funded our operations primarily through the sales of equity and convertible debt securities, and certain government and private grants.

 

We have incurred net losses in each year since our inception. Our net losses were approximately $3.6 million and $2.9 million for the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018, we had an accumulated deficit of approximately $76.0 million. Substantially all our net losses have resulted from costs incurred in connection with our research and development programs, clinical trials, intellectual property matters, building our manufacturing and sales capabilities, and from general and administrative costs associated with our operations. As discussed in more detail under “Liquidity and Capital Resources”, there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued, and we plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations.

 

14

 

 

Financial Overview

 

Revenue

 

We currently have a portfolio of enabling and delivery products, from which we have generated modest revenue.

 

Cost of Goods Sold

 

Cost of goods sold includes the costs of raw materials and components, manufacturing personnel and facility costs and other indirect and overhead costs associated with manufacturing our enabling and delivery products.

 

Research and Development Expenses

 

Our research and development expenses consist primarily of:

  

 

salaries and related overhead expenses, which include share-based compensation and benefits for personnel in research and development functions;

     
  fees paid to consultants and contract research organizations, or CROs, including in connection with our preclinical studies and clinical trials and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial management and statistical compilation and analysis;
     
  costs related to acquiring and manufacturing clinical trial materials;
     
  costs related to compliance with regulatory requirements; and
     
  payments related to licensed products and technologies.

 

 

We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress of completion of specific tasks using information and data provided to us by our vendors and clinical sites. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and the services are performed.

 

We plan to increase our research and development expenses for the foreseeable future as we continue the pivotal CardiAMP Heart Failure Trial, advance the pivotal CardiAMP Chronic Myocardial Ischemia Trial, further develop the CardiAMP and CardiALLO Cell Therapy Systems, and subject to the availability of additional funding, develop other therapeutic candidates for additional indications. We typically use our employee and infrastructure resources across multiple research and development programs, and accordingly, we have not historically allocated resources specifically to our individual programs.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration, sales, corporate development and administrative support functions, including share-based compensation expenses and benefits. Other selling, general and administrative expenses include sales commissions, rent, accounting and legal services, obtaining and maintaining patents, the cost of consultants, occupancy costs, insurance premiums and information systems costs.

  

Other Income (Expense)

 

Other income and expense consists primarily of interest income we earn on our cash, cash equivalents and investments.

  

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various judgements that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not clear from other sources. Actual results may differ from these estimates under different assumptions or conditions. 

  

15

 

 

Apart from the adoption of ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606) on January 1, 2018, which led to an amended revenue policy described below, there were no material changes during the three months ended March 31, 2018 in our critical accounting estimates or accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K.

 

Revenue Recognition

 

Net product revenue – We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.

 

Collaboration agreement revenue – Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.

 

Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.

 

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

 

16

 

 

 

Results of Operations

  

Comparison of Three Months Ended March 31, 2018 and 2017

 

The following table summarizes our results of operations for the three months ended March 31, 2018 and 2017 (in thousands):

 

   

Three months ended March 31,

 
   

2018

   

2017

 

Revenue:

               

Net product revenue

  $ 82     $ 109  

Collaboration agreement revenue

    117       28  

Total revenue

    199       137  

Costs and expenses:

               

Cost of goods sold

    157       175  

Research and development

    1,955       1,033  

Selling, general and administrative

    1,707       1,804  

Total costs and expenses

    3,819       3,012  

Operating loss

    (3,620 )     (2,875 )

Other income (expense):

               

Interest income

    36        

Other income (expense)

          (1 )

Total other income (expense), net

    36       (1 )

Net loss

  $ (3,584 )   $ (2,876 )

 

Revenue.    Revenue increased by approximately $62,000 in the three months ended March 31, 2018 compared to the three months ended March 31, 2017 primarily due to increased revenue earned under programs with our collaborative partners due to the adoption of Topic 606. We expect overall sales volumes to increase modestly in 2018, resulting in moderate growth in net product revenue year over year.

 

Cost of Goods Sold.    Cost of goods sold decreased by approximately $18,000 in the three months ended March 31, 2018 compared to the three months ended March 31, 2017 primarily due to a decrease in product sales volumes. We expect cost of goods sold to increase moderately in 2018 due to growth in net product revenues during the latter half of the year.

 

Research and Development Expenses. Research and development expenses increased by approximately $922,000 in the three months ended March 31, 2018 compared to the three months ended March 31, 2017 primarily due to increased expenses incurred in conducting the ongoing pivotal CardiAMP Heart Failure Trial and in the development of the CardiALLO Cell Therapy System. These expenses include fees paid to consultants and contract research organizations (CRO) and additional personnel costs. We expect research and development expenses to continue to increase as enrollment accelerates in the CardiAMP Heart Failure Trial and we further develop the CardiAMP and CardiALLO platforms.

 

Selling, General and Administrative Expenses.    Selling, general and administrative expenses for the three months ended March 31, 2018 totaled $1,707,000, which was a 5.4% decrease as compared to $1,804,000 for three months ended March 31, 2017. We expect selling, general and administrative expenses for 2018 to increase moderately in the latter half of 2018 compared to 2017, as we continue to enhance and strengthen the supporting staff and infrastructure needed to support the CardiAMP Heart Failure Trial and development of our therapeutic programs.  

 

Liquidity and Capital Resources

 

We have incurred net losses each year since our inception and as of March 31, 2018, we had an accumulated deficit of approximately $76.0 million. We anticipate that we will continue to incur net losses for the next several years.

  

We have funded our operations principally through the sales of equity and convertible debt securities as well as the cash acquired through the reverse merger transaction completed on October 24, 2016. As of March 31, 2018, we had cash and cash equivalents of approximately $9.7 million.

 

17

 

 

The following table shows a summary of our cash flows for the periods indicated (in thousands):

 

   

Three months ended March 31,

 
   

2018

   

2017

 

Net cash provided by (used in):

               

Operating activities

  $ (3,036 )     (2,278 )

Investing activities

    (5 )     (64 )

Financing activities

    5       22  

Net decrease in cash and cash equivalents

  $ (3,036 )   $ (2,320 )

 

Cash Flows from Operating Activities. The increase in overall spending for operating activities of $758,000 in the three months ended March 31, 2018 compared to the three months ended March 31, 2017 related primarily to increased cash outflows to conduct the pivotal CardiAMP Heart Failure Trial, further develop the CardiAMP and CardiALLO programs and to build the supporting infrastructure to sustain these efforts and support operations as a public company. We expect spending to increase as we continue enrolling and treating patients in the CardiAMP Heart Failure Trial, further develop the CardiAMP and CardiALLO cell therapy systems and continue to strengthen and enhance the supporting organization.

 

Cash Flows from Investing Activities. Net cash used in investing activities of $5,000 during the three months ended March 31, 2018 consisted of the purchases of property and equipment.

 

Cash Flows from Financing Activities. Net cash provided by financing activities of $5,000 during the three months ended March 31, 2018 consisted of the proceeds from the exercise of stock options.

 

Future Funding Requirements

 

To date, we have generated modest revenue from sales of our approved products. We do not know when, or if, we will generate any revenue from our development stage biotherapeutic programs. We do not expect to generate any revenue from sales of our CardiAMP or CardiALLO therapeutic candidates unless and until we obtain regulatory approval. At the same time, we expect our expenses to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our therapeutic candidates. In addition, subject to obtaining regulatory approval for any of our therapeutic candidates and companion diagnostic, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need additional funding in connection with our continuing operations.  

 

Based upon our current operating plan, we believe that the cash and cash equivalents of $9.7 million as of March 31, 2018 are sufficient to fund our operations into the fourth quarter of 2018. In order to continue to further the development of our lead therapeutic candidates, the CardiAMP Cell Therapy System, and our second therapeutic candidate, the CardiALLO Cell Therapy System, through and beyond the fourth quarter of 2018, we will be required to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our therapeutic candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our therapeutic candidates.

 

Our future capital requirements will depend on many factors, including:

 

 

the progress, costs, results and timing of our CardiAMP and CardiALLO clinical trials and related development programs;

 

 

FDA acceptance of our CardiAMP and CardiALLO therapies for heart failure and for other potential indications;

 

 

the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;

 

 

the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities;

 

 

the number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;

 

18

 

 

 

the ability of our product candidates to progress through clinical development successfully;

 

 

our need to expand our research and development activities;

 

 

the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;

 

 

our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

 

 

the general and administrative expenses related to being a public company;

 

 

our need and ability to hire additional management and scientific, medical and sales personnel;

 

 

the effect of competing technological and market developments; and

 

 

our need to implement additional internal systems and infrastructure, including financial and reporting systems.

 

Until such time that we can generate meaningful revenue from the sales of approved therapies and products, if ever, we expect to finance our operating activities through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our Common Stock holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our Common Stock holders. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, products or therapeutic candidates or to grant licenses on terms that may not be favorable to us. 

 

Our condensed consolidated financial statements as of and for the three months ended March 31, 2018 have been prepared on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. Due to the factors described above, there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. Our ability to continue as a going concern will depend in a large part, on our ability to raise additional capital. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

 

The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we are unable to continue as a going concern, we may be forced to liquidate assets. In such a scenario, the values received for assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.

 

Off-Balance Sheet Arrangements

 

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the Securities and Exchange Commission.

 

Recent Accounting Pronouncements

 

See Note 2 of our notes to condensed consolidated financial statements for information regarding recent accounting pronouncements that are of significance or potential significance to us.

 

19

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

There have been no material changes in our market risks during the quarter ended March 31, 2018.

 

Our exposure to market risk is currently limited to our cash and cash equivalents, all of which have maturities of less than three months. The goals of our investment policy are preservation of capital, maintenance of liquidity needs, and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk or departing from our investment policy. We currently do not hedge interest rate exposure. Because of the short-term nature of our cash equivalents, we do not believe that an increase in market rates would have a material negative impact on the value of our portfolio.

 

Interest Rate Risk

 

As of March 31, 2018, based on current interest rates and total borrowings outstanding, a hypothetical 100 basis point increase or decrease in interest rates would have an immaterial pre-tax impact on our results of operations.

 

 

Foreign Currency Exchange Risks

 

We are a U.S. entity and our functional currency is the U.S. dollar. The vast majority of our revenues were derived from sales in the United States. We have business transactions in foreign currencies, however, we believe we do not have significant exposure to risk from changes in foreign currency exchange rates at this time. We do not currently engage in hedging or similar transactions to reduce our foreign currency risks. We will continue to monitor and evaluate our internal processes relating to foreign currency exchange, including the potential use of hedging strategies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as our controls are designed to do, and management necessarily was required to apply its judgment in evaluating the risk related to controls and procedures.

 

In connection with the preparation of this Quarterly Report on Form 10-Q, as of March 31, 2018, an evaluation was performed under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of March 31, 2018, our disclosure controls and procedures were, in design and operation, effective.

 

 

Changes in Internal Control over Financial Reporting

 

There were no changes to our internal control over financial reporting identified in connection with the evaluation required by rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

20

 

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management does not believe that we are a party to any currently pending legal proceedings. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial position, results of operations, or cash flows.

 

ITEM 1A. RISK FACTORS

 

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect our business, financial condition, or future results. The risks described in this report and in our Annual Report on 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBIT INDEX

 

The exhibits listed in the Exhibit Index to this Quarterly Report on Form 10-Q are incorporated herein by reference.

 

21

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

BIOCARDIA, INC.

(Registrant)

 

 

 

 

 

 

 

 

 

Date:     May 10, 2018

By:

/s/ Peter Altman

 

 

 

Peter Altman

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

       
       
Date:     May 10, 2018 By: /s/ David McClung  
    David McClung  
    Chief Financial Officer  
    (Principal Financial and Accounting Officer)  

 

22

 

 

EXHIBIT INDEX

 

Exhibit

Number 

Exhibit Description

31.1*

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Principal Financial Officer Pursuant to Rule 13a-14(b) and Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS+

 XBRL Instance Document

101.SCH+

 XBRL Taxonomy Extension Schema Document

101.CAL+

 XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF+

 XBRL Taxonomy Extension Definition Linkbase Document

101.LAB+

 XBRL Taxonomy Extension Label Linkbase Document

101.PRE+

 XBRL Taxonomy Extension Presentation Linkbase Document

 

*

Filed herewith.

**

Furnished herewith.

+

The financial information contained in these XBRL documents is unaudited and is furnished, not filed with the Securities and Exchange Commission.


23

EX-31.1 2 ex_112872.htm EXHIBIT 31.1 ex_112872.htm

 

Exhibit 31.1

 

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Peter Altman, certify that:

 

1.       I have reviewed this Quarterly Report on Form 10-Q of BioCardia, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.       The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.       The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date:  May 10, 2018

 

   

/s/ Peter Altman

 
   

Name: Peter Altman

 
   

Title: President and Chief Executive Officer

(Principal Executive Officer)

 
EX-31.2 3 ex_112873.htm EXHIBIT 31.2 ex_112873.htm

 

Exhibit 31.2

 

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, David McClung, certify that:

 

1.       I have reviewed this Quarterly Report on Form 10-Q of BioCardia, Inc.;

 

2.       Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.       Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.       The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

  

5.       The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

   Date:  May 10, 2018 

 

   

/s/ David McClung

 
   

Name: David McClung

 
   

Title: Chief Financial Officer

(Principal Financial Officer)

 
EX-32.1 4 ex_112874.htm EXHIBIT 32.1 ex_112874.htm

Exhibit 32.1

 

Certification of Principal Executive Officer

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Peter Altman, the President and Chief Executive Officer of BioCardia, Inc. (the "Company"), hereby certify, that, to my knowledge:

 

1.     The Quarterly Report on Form 10-Q for the period ended March 31, 2018 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Date:  May 10, 2018

 

   

/s/ Peter Altman

 
   

Name: Peter Altman

 
   

Title: President and Chief Executive Officer

(Principal Executive Officer)

 
EX-32.2 5 ex_112875.htm EXHIBIT 32.2 ex_112875.htm

Exhibit 32.2

 

Certification of Principal Financial Officer

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, David McClung, the Chief Financial Officer of BioCardia, Inc. (the “Company”), hereby certify, that, to my knowledge:

 

 

1.

The Quarterly Report on Form 10-Q for the period ended March 31, 2018 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

     
  2.  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:  May 10, 2018

 

   

/s/ David McClung

 
   

Name: David McClung

 
   

Title: Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

 

EX-101.INS 6 bcda-20180331.xml XBRL INSTANCE DOCUMENT <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Accrued </div><div style="display: inline; font-weight: bold;">Expenses and Other Current </div><div style="display: inline; font-weight: bold;">Liabilities</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Accrued expenses and other current liabilities consisted of the following (in&nbsp;thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,<br /> 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Accrued expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">579</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">539</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Grant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">654</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Customer deposits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,323</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> 1323000 1263000 P4Y P1Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(b)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Liquidity</div></div></div> </td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$76.0</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018. </div>Management expects operating losses and negative cash flows to continue through the next several years. Based on management&#x2019;s current plans, management believes cash and cash equivalents of&nbsp; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.7</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>are sufficient to fund the Company into the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> These factors raise substantial doubt about our ability to continue as a going concern beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date these financial statements are issued. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty.</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP cell therapy system, and our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> therapeutic candidate, the CardiALLO cell therapy system, through and beyond the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available, we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.</div> </td> </tr> </table></div></div></div></div></div> 654000 663000 0.05 0.05 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,<br /> 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Accrued expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">579</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">539</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Grant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">654</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Customer deposits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,323</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended March 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Selling, general and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Share-based compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">622</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> 5300000 false --12-31 Q1 2018 2018-03-31 10-Q 0000925741 38241244 Yes Accelerated Filer BioCardia, Inc. No No bcda 738000 902000 127000 95000 579000 539000 779000 758000 84157000 83537000 45000 233000 37000 122000 30000 41000 197000 172000 388000 409000 615000 622000 6000 6000 5618854 3816927 77552 61333 5696406 3878260 10411000 13538000 10205000 13315000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(a)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Basis of Preparation</div></div></div> </td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and cash flows for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The results for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results to be expected for the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or for any other interim period or for any other future year.</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#x2019;s Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>filed with the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 16, 2018.</div></td> </tr> </table></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Summary of Business and Basis of Presentation</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(a)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Description of Business</div></div></div> </td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">BioCardia, Inc., (We or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the CardiAMP cell therapy system and our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> therapeutic candidate is the CardiALLO cell therapy system. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property.</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">We have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> enabling device product lines: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) the CardiAMP cell processing system; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) the Helix biotherapeutic delivery system, or Helix; and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) the Morph vascular access product line, or Morph. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.</td></tr></table></div> 15000 9653000 12689000 21352000 19032000 9653000 9653000 12689000 12689000 -3036000 -2320000 0.001 0.001 100000000 100000000 38241244 38218660 38241244 38218660 38000 38000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(d)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Principles of Consolidation</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.</div></div></div></div></div></div> 157000 175000 3819000 3012000 90000 61000 83000 81000 60000 167000 0 22000 13000 22000 13000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> share-based compensation was capitalized during the periods presented. Share-based compensation expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was recorded as follows (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</div> <div> <table style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended March 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">197</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Selling, general and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">388</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">Share-based compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">615</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">622</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The following table summarizes the activity of stock options and related information:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div> <table style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,213,100</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.96</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,429,075</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.60</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,488</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.80</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,833</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.56</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, March 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,618,854</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.85</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The weighted average grant-date fair value of options granted during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.86</div>&nbsp;per share.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Employee Share-Based Compensation (Stock Options)</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>we granted stock options to certain&nbsp;non-employee directors and employees to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,429,075</div> shares of common stock. The fair value of each option grant was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:&nbsp;&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div> <table style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.66%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Dividend yield</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">None</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25%</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Unrecognized share-based compensation for employee options granted through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>is approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.7</div> million to be recognized over a remaining weighted average service period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.1</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Non-Employee Director</div><div style="display: inline; font-style: italic;"> Share-Based Compensation (RSUs)</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The following summarizes the activity of non-vested RSUs:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</div> <div> <table style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant date</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">fair value</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">per share</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97,996</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.71</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">RSUs granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">RSUs vested</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,444</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.04</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">RSUs forfeited</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, March 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77,552</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.09</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">Unrecognized share-based compensation for employee RSUs granted through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>is approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$441,000</div> to be recognized over a remaining weighted average service period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.7</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Nonemployee Share-Based Compensation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> grant any options to purchase shares of common stock to consultants. Options granted to consultants have been granted in exchange for consulting services to be rendered and vest over the term specified in the grant, which correlates to the period the services are rendered. We recorded approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$45,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$233,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, as nonemployee share-based compensation expense.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The Company accounts for share-based compensation arrangements with nonemployees, using the Black-Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, the Company revalues the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div> <table style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.83%</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80%</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;">Dividend yield</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;8.4</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.8</div></td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> -0.09 -0.08 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Net Loss per Share</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to our net loss position.&nbsp;&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div> <table style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended March 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options to purchase common stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,618,854</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,816,927</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77,552</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61,333</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,696,406</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,878,260</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div></div> 0.35 0.21 P3Y36D P1Y255D 441000 6700000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurement</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>&nbsp;levels:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Level&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> &#x2013; quoted prices in active markets for identical assets and liabilities</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Level&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> &#x2013; observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Level&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> &#x2013; unobservable inputs that are supported by little or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> market activity and that are significant to the fair value of the assets or liabilities.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left; text-indent: 0pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">The following table sets forth the fair value of our financial assets measured on a recurring basis as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017 </div>and indicates the fair value hierarchy utilized to determine such fair value (in thousands).</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div> <table style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of March 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 48%;">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,653</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,653</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0pt;">&nbsp;</div> <div> <table style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of December 31, 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,689</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,689</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></div><div style="display: inline; font-weight: bold;">)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statement of operations due to the Company&#x2019;s net loss and a full valuation allowance on the resulting deferred tax assets.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>we retain a full valuation allowance on our deferred tax assets in all jurisdictions. The realization of our deferred tax assets depends primarily on our ability to generate future taxable income which is uncertain. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe that our deferred tax assets are realizable on a more-likely-than-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 22, 2017, </div>the Tax Cuts and Jobs Act (H.R. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) (the Tax Act) was signed into law. The new law resulted in significant changes to the U.S. corporate income tax system. These changes included the reduction of the corporate income tax rate from a maximum rate of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35%</div> to&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%</div> and the elimination or reduction of certain domestic deductions and credits.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;">The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> provisional charge related to the Tax Act was an estimate and the measurement of net deferred tax assets is subject to further analysis and potential correlative adjustments as developing interpretations and guidance from the U.S. Treasury Department, the Internal Revenue Service, and other standard setting bodies provide additional clarifications of the provisions of the Tax Act. Updated guidance and regulations could result in changes to this provisional charge during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> when the analysis is complete, and, in accordance with the guidance in Staff Accounting Bulletin <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,</div> we will continue to monitor guidance and make necessary adjustments. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> measurement-period adjustments were made during the quarter ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018.</div></div></div> 0 0 -164000 -249000 32000 47000 34000 157000 2000 6000 -35000 1000 -43000 9000 -63000 -104000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Inventories</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in&nbsp;thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div> <table style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Raw materials</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Work in process</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Finished goods</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">148</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Write downs for excess or expired inventory are based on management&#x2019;s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in recording additional write downs for excess or expired inventory in the future. Charges to cost of goods sold for inventory write-downs, reserve adjustments, scrap, shrinkage and expired inventories totaled approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div></div> 55000 29000 148000 191000 78000 70000 15000 92000 2000 9000 2204000 2413000 10411000 13538000 2121000 2332000 5000 22000 -5000 -64000 -3036000 -2278000 -3584000 -2876000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">f</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncement</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014,&nbsp;</div>the FASB issued Topic&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> which provides comprehensive guidance for revenue recognition. Topic&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>&nbsp;affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings.&nbsp;</div> </td> </tr> </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">On&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we adopted Topic&nbsp;<div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></div> using the cumulative effect adoption method. Results for reporting periods beginning after&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>&nbsp;are presented under Topic&nbsp;<div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></div>, while prior period amounts are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> adjusted and continue to be reported in accordance with our historic accounting under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605.</div> The adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016,&nbsp;</div>the FASB issued ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>&nbsp;(ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>&nbsp;changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>&nbsp;on&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018&nbsp;</div>and the adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> Compensation &#x2013; Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>) Scope of Modification Accounting (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div>). The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div> We adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>and the adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">g</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>) (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div>), which supersedes existing guidance on accounting for leases in Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div>) and generally requires all leases to be recognized in the consolidated balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is effective for annual and interim reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018; </div>early adoption is permitted. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> plan to elect early adoption. The provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> are to be applied using a modified retrospective approach. The Company is currently assessing the future impact of this ASU on its consolidated financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> or are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believed by management to have a material impact on the Company&#x2019;s financial statement presentation or disclosures.</div></div></div></div></div></div> 36000 -1000 -3620000 -2875000 54000 54000 -1000 36000 5000 64000 0.001 0.001 25000000 25000000 0 0 0 0 277000 340000 5000 22000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Property and Equipment, Net</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Property and equipment, net consisted of the following (in&nbsp;thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;</div> <div> <table style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 66%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,<br /> 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Computer equipment and software</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Laboratory and manufacturing equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Furniture and fixtures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Property and equipment, gross</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">931</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">927</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(779</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(758</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">152</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Depreciation expense totaled approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$13,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div></div> 110000 106000 447000 447000 48000 48000 326000 326000 931000 927000 152000 169000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 66%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,<br /> 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Computer equipment and software</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Laboratory and manufacturing equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Furniture and fixtures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Property and equipment, gross</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">931</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">927</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(758</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">152</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></div><div style="display: inline; font-weight: bold;">)&nbsp;&nbsp;&nbsp; &nbsp;Related Party Transactions</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>we granted an option to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,977</div> shares of common stock, with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>-year vesting period and an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.80</div> per share, to OPKO Health, Inc. (&#x201c;OPKO&#x201d;) as consideration for consulting services to be provided by OPKO. We recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$122,000</div> as share-based compensation expense related to the OPKO stock option during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. The estimated grant-date fair value of the option was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.3</div> million. The term of the consulting agreement is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> years and will be automatically renewed for successive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of the outstanding shares of the Company&#x2019;s common stock and OPKO itself is also a beneficial owner of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of the outstanding shares of the Company&#x2019;s common stock.&nbsp;</div></div> 1955000 1033000 -75988000 -72450000 82000 109000 117000 28000 199000 137000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(e)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Changes to </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Significant Accounting Policies</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">Our significant accounting policies are described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> of the notes to the financial statements included in our Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K filed for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Apart from the adoption of ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div>&nbsp;Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>which led to an amended revenue policy, as described in the following paragraphs, there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> changes to those policies.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 45pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Net product revenue</div>&nbsp;&#x2013; We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Collaboration agreement revenue</div>&nbsp;&#x2013; Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.</div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended March 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options to purchase common stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,618,854</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,816,927</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77,552</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61,333</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,696,406</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,878,260</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of March 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 48%;">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,653</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,653</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of December 31, 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 48%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Assets:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 9pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,689</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,689</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 68%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Raw materials</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Work in process</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Finished goods</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">148</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant date</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">fair value</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">per share</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97,996</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.71</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">RSUs granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">RSUs vested</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,444</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">RSUs forfeited</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, March 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77,552</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255); padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,213,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,429,075</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,488</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Stock options cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,833</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.56</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Balance, March 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,618,854</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.85</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.66%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Dividend yield</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">None</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.83%</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80%</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;">Dividend yield</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;8.4</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.8</div></td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td nowrap="nowrap" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> 1707000 1804000 615000 622000 P4Y 97996 77552 8.71 8.09 20444 11.04 0 0 0.81 0.8 0.0266 0.0283 20833 1429075 0 418977 1429075 1.86 4213100 5618854 1.80 2.96 2.85 1.80 7.56 2.60 P6Y91D P8Y146D P8Y292D <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 4%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>)</div></div> </td> <td style="vertical-align: top; width: 96%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Significant Accounting Policies</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(a)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Basis of Preparation</div></div></div> </td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> and cash flows for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The results for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results to be expected for the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or for any other interim period or for any other future year.</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#x2019;s Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div>filed with the SEC on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 16, 2018.</div></td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(b)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Liquidity</div></div></div> </td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;">We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$76.0</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018. </div>Management expects operating losses and negative cash flows to continue through the next several years. Based on management&#x2019;s current plans, management believes cash and cash equivalents of&nbsp; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.7</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>are sufficient to fund the Company into the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> These factors raise substantial doubt about our ability to continue as a going concern beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date these financial statements are issued. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty.</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%;">&nbsp;</td> </tr> <tr> <td style="vertical-align: middle; width: 5%;">&nbsp;</td> <td style="vertical-align: top; width: 3%;">&nbsp;</td> <td style="vertical-align: top; width: 92%; text-align: justify;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP cell therapy system, and our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> therapeutic candidate, the CardiALLO cell therapy system, through and beyond the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available, we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(d)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Principles of Consolidation</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(e)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Changes to </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Significant Accounting Policies</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">Our significant accounting policies are described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> of the notes to the financial statements included in our Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K filed for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> Apart from the adoption of ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div>&nbsp;Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>which led to an amended revenue policy, as described in the following paragraphs, there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> changes to those policies.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 45pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Net product revenue</div>&nbsp;&#x2013; We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Collaboration agreement revenue</div>&nbsp;&#x2013; Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">f</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncement</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">In&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014,&nbsp;</div>the FASB issued Topic&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> which provides comprehensive guidance for revenue recognition. Topic&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>&nbsp;affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings.&nbsp;</div> </td> </tr> </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">On&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we adopted Topic&nbsp;<div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></div> using the cumulative effect adoption method. Results for reporting periods beginning after&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>&nbsp;are presented under Topic&nbsp;<div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></div>, while prior period amounts are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> adjusted and continue to be reported in accordance with our historic accounting under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605.</div> The adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016,&nbsp;</div>the FASB issued ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>&nbsp;(ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>&nbsp;changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>&nbsp;on&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018&nbsp;</div>and the adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> Compensation &#x2013; Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>) Scope of Modification Accounting (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div>). The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div> We adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>and the adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">&nbsp;</div> <table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: middle; width: 5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">g</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>) (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div>), which supersedes existing guidance on accounting for leases in Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div>) and generally requires all leases to be recognized in the consolidated balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is effective for annual and interim reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018; </div>early adoption is permitted. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> plan to elect early adoption. The provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> are to be applied using a modified retrospective approach. The Company is currently assessing the future impact of this ASU on its consolidated financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> or are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believed by management to have a material impact on the Company&#x2019;s financial statement presentation or disclosures.</div></div> 2488 8207000 11125000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align: middle; width: 5%;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> </td> <td style="vertical-align: top; width: 3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></div> </td> <td style="vertical-align: top; width: 92%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.</div></div></div></div></div></div> 38236056 38137881 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2016-08-01 2016-08-31 0000925741 2017-01-01 2017-03-31 0000925741 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0000925741 bcda:CostOfGoodsSoldMember 2017-01-01 2017-03-31 0000925741 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0000925741 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0000925741 bcda:CollaborationAgreementMember 2017-01-01 2017-03-31 0000925741 us-gaap:ProductMember 2017-01-01 2017-03-31 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2017-01-01 2017-03-31 0000925741 bcda:NonEmployeesMember 2017-01-01 2017-03-31 0000925741 2017-01-01 2017-12-31 0000925741 2018-01-01 2018-03-31 0000925741 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000925741 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000925741 bcda:NonemployeeStockOptionsMember 2018-01-01 2018-03-31 0000925741 bcda:NonemployeeStockOptionsMember srt:MaximumMember 2018-01-01 2018-03-31 0000925741 bcda:NonemployeeStockOptionsMember srt:MinimumMember 2018-01-01 2018-03-31 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000925741 bcda:CostOfGoodsSoldMember 2018-01-01 2018-03-31 0000925741 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0000925741 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000925741 bcda:CollaborationAgreementMember 2018-01-01 2018-03-31 0000925741 us-gaap:ProductMember 2018-01-01 2018-03-31 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2018-01-01 2018-03-31 0000925741 bcda:ConsultantsMember 2018-01-01 2018-03-31 0000925741 bcda:NonEmployeesMember 2018-01-01 2018-03-31 0000925741 bcda:NonemployeeDirectorsAndEmployeesMember 2018-01-01 2018-03-31 0000925741 us-gaap:ScenarioForecastMember 2018-01-01 2018-12-31 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2016-08-31 0000925741 bcda:ChairmanAndChiefExecutiveOfficerOfOPKOMember 2016-08-31 0000925741 bcda:OPKOMember 2016-08-31 0000925741 2016-12-31 0000925741 2017-03-31 0000925741 2017-12-31 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000925741 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 bcda:ComputerEquipmentAndSoftwareMember 2017-12-31 0000925741 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000925741 bcda:LaboratoryAndManufacturingEquipmentMember 2017-12-31 0000925741 us-gaap:LeaseholdImprovementsMember 2017-12-31 0000925741 2018-03-31 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0000925741 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000925741 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000925741 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000925741 us-gaap:FairValueMeasurementsRecurringMember 2018-03-31 0000925741 bcda:ComputerEquipmentAndSoftwareMember 2018-03-31 0000925741 us-gaap:FurnitureAndFixturesMember 2018-03-31 0000925741 bcda:LaboratoryAndManufacturingEquipmentMember 2018-03-31 0000925741 us-gaap:LeaseholdImprovementsMember 2018-03-31 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2018-03-31 0000925741 2018-05-07 EX-101.SCH 7 bcda-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Summary of Business and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Fair Value Measurement link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Property and Equipment, Net link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 012 - Document - Note 8 - Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 10 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 3 - Fair Value Measurement (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 5 - Property and Equipment, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 7 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 8 - Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 7 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 7 - Share-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 10 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 bcda-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bcda-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bcda-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Note 3 - Fair Value Measurement Note 4 - Inventories Risk-free interest rate Risk-free interest rate Note 5 - Property and Equipment, Net Note 6 - Accrued Expenses and Other Current Liabilities Note 7 - Share-based Compensation Note 8 - Net Loss Per Share Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Note 4 - Inventories - Summary of Inventories (Details) Income Tax Disclosure [Text Block] Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) Volatility Volatility Share-based compensation Other assets Note 7 - Share-based Compensation - Stock Option Activity (Details) Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) Title of Individual [Axis] Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) Relationship to Entity [Domain] Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) Expected term (in years) (Year) Notes To Financial Statements Notes To Financial Statements [Abstract] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] RSUs granted, Weighted average grant date fair value per share (in dollars per share) RSUs vested, Weighted average grant date fair value per share (in dollars per share) RSUs forfeited, Weighted average grant date fair value per share (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, Weighted average grant date fair value per share (in dollars per share) Balance, Weighted average grant date fair value per share (in dollars per share) RSUs forfeited, Shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance, Shares (in shares) Balance, Shares (in shares) us-gaap_Depreciation Depreciation, Total RSUs granted, Shares (in shares) Depreciation and amortization us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod RSUs vested, Shares (in shares) Collaboration Agreement [Member] Represents the information pertaining to the collaboration agreement. Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Assets: us-gaap_AssetsCurrent Total current assets us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash and cash equivalents us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Common stock, $0.001 par value, 100,000,000 shares authorized as of March 31, 2018 and December 31, 2017 respectively; 38,241,244 and 38,218,660 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Balance, weighted average exercise price, beginning of period (in dollars per share) Balance, weighted average exercise price, end of period (in dollars per share) Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Common stock, shares authorized (in shares) Stock options cancelled, weighted average exercise price (in dollars per share) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Stock options granted, weighted average exercise price (in dollars per share) Revenue from Contract with Customer [Policy Text Block] Stock options exercised, weighted average exercise price (in dollars per share) Accrued expenses Range [Domain] Maximum [Member] Supplemental disclosure of noncash investing activity: Minimum [Member] Accounts payable Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Stock options outstanding, beginning of period (in shares) Stock options outstanding, end of period (in shares) Product and Service [Domain] Range [Axis] Accounts payable recognized for the purchase of equipment bcda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value Grant-date fair value of non-vested options outstanding. Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2018 and December 31, 2017 Preferred stock, shares issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Prepaid expenses Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Inventory Total Preferred stock, par value (in dollars per share) Total revenue Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Fair Value Hierarchy and NAV [Axis] Current liabilities: Product [Member] us-gaap_Assets Total assets Deferred revenue us-gaap_IncreaseDecreaseInDeferredRevenue us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Statement [Line Items] Allowance for doubtful accounts Furniture and Fixtures [Member] Accounts receivable, net of allowance for doubtful accounts of $6 at March 31, 2018 and December 31, 2017, respectively Additional paid-in capital Revenue: Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders’ equity: Leasehold Improvements [Member] Other expense, net Property, Plant and Equipment, Type [Axis] us-gaap_NonoperatingIncomeExpense Total other income (expense), net Property, Plant and Equipment, Type [Domain] Business Description and Basis of Presentation [Text Block] Equity Award [Domain] Customer deposits Current assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net loss Net loss Restricted Stock Units (RSUs) [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total liabilities Interest income us-gaap_OperatingIncomeLoss Operating loss Employee Stock Option [Member] Other income (expense): us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_DeferredTaxLiabilities Deferred Tax Liabilities, Net, Total us-gaap_NetCashProvidedByUsedInInvestingActivities Net used in in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Accrued expenses and other current liabilities Total Amount of accrued liabilities and liabilities classified as other, due within one year or the normal operating cycle, if longer. Cost of goods sold us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Net decrease in cash and cash equivalents us-gaap_InventoryWriteDown Inventory Write-down us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Non-employee Directors and Employees [Member] Related to certain non-directors and employees. Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Accrued Liabilities and Other Current Liabilities Disclosure [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Grant liability Amount of obligations incurred for grants, payable within one year or the normal operating cycle, if longer. Property and equipment, gross us-gaap_CostsAndExpenses Total costs and expenses Costs and expenses: Investing activities: Earnings Per Share [Text Block] Proceeds from the exercise of common stock options Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit), Total Accrued liabilities Equity Components [Axis] Equity Component [Domain] Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Deferred revenue Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Share-based compensation expense us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense, Total Deferred rent us-gaap_IncreaseDecreaseInDeferredLiabilities Amendment Flag Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Selling, General and Administrative Expenses [Member] Going Concern and Liquidity [Policy Text Block] Disclosure of accounting policy for reporting when there is, or is not, a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations. Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date Cost of Goods Sold [Member] Related to the cost of goods sold. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses Computer Equipment and Software [Member] Related to computer equipment and software. Research and Development Expense [Member] Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Laboratory and Manufacturing Equipment [Member] Related to laboratory and manufacturing equipment. Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] Document Type Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Consultants [Member] Represents information pertaining to consultants. Schedule of Share-based Compensation, Expense [Table Text Block] Tabular disclosure of the components of the allocated share-based compensation expense. Non-employees [Member] Represents information pertaining to non-employees. Non-employee Stock Options [Member] Related to non-employee stock options. Weighted-average shares used in computing net loss per share, basic and diluted (in shares) Antidilutive securities (in shares) us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Net loss per share, basic and diluted (in dollars per share) Entity Central Index Key Entity Registrant Name Scenario, Forecast [Member] Entity [Domain] Legal Entity [Axis] Statement [Table] Scenario [Axis] Scenario, Unspecified [Domain] Statement of Financial Position [Abstract] Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding (in shares) Income Statement [Abstract] us-gaap_IncreaseDecreaseInInventories Inventory Trading Symbol Consulting Services [Member] Represents information pertaining to consulting services. bcda_ConsultingAgreementTermLengthOfAutomaticRenewalPeriods Consulting Agreement, Term, Length of Automatic Renewal Periods Represents the length of time of each of the automatic renewal periods for the term of a consulting agreement. OPKO [Member] Represents information pertaining to OPKO Health, Inc. ("OPKO"). bcda_ConsultingAgreementTerm Consulting Agreement, Term Represents the term of a consulting agreement. Chairman and Chief Executive Officer of OPKO [Member] Represents information pertaining to the Chairman and Chief Executive Officer of OPKO. us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Stock options exercised (in shares) us-gaap_TableTextBlock Notes Tables bcda_RelatedPartyOwnershipPercentage Related Party, Ownership Percentage Represents the percentage of the entity that is owned by a specified related party. Related Party [Axis] Related Party [Domain] Selling, general and administrative Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Financing activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Stock options cancelled (in shares) us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Raw materials us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Finished goods Work in process Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Research and development Deferred rent Changes in operating assets and liabilities: us-gaap_StockholdersEquity Total stockholders’ equity us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Schedule of Inventory, Current [Table Text Block] Class of Stock [Axis] EX-101.PRE 11 bcda-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2018
May 07, 2018
Document Information [Line Items]    
Entity Registrant Name BioCardia, Inc.  
Entity Central Index Key 0000925741  
Trading Symbol bcda  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   38,241,244
Document Type 10-Q  
Document Period End Date Mar. 31, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 9,653 $ 12,689
Accounts receivable, net of allowance for doubtful accounts of $6 at March 31, 2018 and December 31, 2017, respectively 127 95
Inventory 148 191
Prepaid expenses 277 340
Total current assets 10,205 13,315
Property and equipment, net 152 169
Other assets 54 54
Total assets 10,411 13,538
Current liabilities:    
Accounts payable 738 902
Accrued expenses and other current liabilities 1,323 1,263
Deferred revenue 60 167
Total current liabilities 2,121 2,332
Deferred rent 83 81
Total liabilities 2,204 2,413
Stockholders’ equity:    
Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2018 and December 31, 2017
Common stock, $0.001 par value, 100,000,000 shares authorized as of March 31, 2018 and December 31, 2017 respectively; 38,241,244 and 38,218,660 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively 38 38
Additional paid-in capital 84,157 83,537
Accumulated deficit (75,988) (72,450)
Total stockholders’ equity 8,207 11,125
Total liabilities and stockholders’ equity $ 10,411 $ 13,538
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Allowance for doubtful accounts $ 6 $ 6
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 25,000,000 25,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 38,241,244 38,218,660
Common stock, shares outstanding (in shares) 38,241,244 38,218,660
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenue:    
Total revenue $ 199 $ 137
Costs and expenses:    
Cost of goods sold 157 175
Research and development 1,955 1,033
Selling, general and administrative 1,707 1,804
Total costs and expenses 3,819 3,012
Operating loss (3,620) (2,875)
Other income (expense):    
Interest income 36
Other expense, net (1)
Total other income (expense), net 36 (1)
Net loss $ (3,584) $ (2,876)
Net loss per share, basic and diluted (in dollars per share) $ (0.09) $ (0.08)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares) 38,236,056 38,137,881
Product [Member]    
Revenue:    
Total revenue $ 82 $ 109
Collaboration Agreement [Member]    
Revenue:    
Total revenue $ 117 $ 28
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Operating activities:    
Net loss $ (3,584) $ (2,876)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 22 13
Share-based compensation 615 622
Changes in operating assets and liabilities:    
Accounts receivable (32) (47)
Inventory 43 (9)
Prepaid expenses 63 104
Accounts payable (164) (249)
Accrued liabilities 34 157
Deferred revenue (35) 1
Deferred rent 2 6
Net cash used in operating activities (3,036) (2,278)
Investing activities:    
Purchase of property and equipment (5) (64)
Net used in in investing activities (5) (64)
Financing activities:    
Proceeds from the exercise of common stock options 5 22
Net cash provided by financing activities 5 22
Net decrease in cash and cash equivalents (3,036) (2,320)
Cash and cash equivalents at beginning of period 12,689 21,352
Cash and cash equivalents at end of period 9,653 19,032
Supplemental disclosure of noncash investing activity:    
Accounts payable recognized for the purchase of equipment $ 15
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 1 - Summary of Business and Basis of Presentation
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]
(
1
)
Summary of Business and Basis of Presentation
 
 
(a)
Description of Business
     
    BioCardia, Inc., (We or the Company), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the CardiAMP cell therapy system and our
second
therapeutic candidate is the CardiALLO cell therapy system. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property.
     
    We have
three
enabling device product lines: (
1
) the CardiAMP cell processing system; (
2
) the Helix biotherapeutic delivery system, or Helix; and (
3
) the Morph vascular access product line, or Morph. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 2 - Significant Accounting Policies
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Significant Accounting Policies [Text Block]
(
2
)
Significant Accounting Policies
 
 
(a)
Basis of Preparation
     
    The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of
March 31, 2018
and for the
three
months ended
March 31, 2018
and
2017
are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position as of
March 31, 2018,
results of operations for the
three
months ended
March 31, 2018
and
2017,
and cash flows for the
three
months ended
March 31, 2018
and
2017.
The results for the
three
months ended
March 31, 2018
are
not
necessarily indicative of the results to be expected for the year ending
December 31, 2018
or for any other interim period or for any other future year.
     
    These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form
10
-K for the year ended
December 31, 2017,
filed with the SEC on
March 16, 2018.
 
 
(b)
Liquidity
     
    We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of
$76.0
million as of
March 31, 2018.
Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of 
$9.7
million as of
March 31, 2018
are sufficient to fund the Company into the
fourth
quarter of
2018.
These factors raise substantial doubt about our ability to continue as a going concern beyond
one
year from the date these financial statements are issued. The financial statements do
not
include any adjustments that might result from the outcome of this uncertainty.
     
   
Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP cell therapy system, and our
second
therapeutic candidate, the CardiALLO cell therapy system, through and beyond the
fourth
quarter of
2018,
will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are
not
available, we
may
be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that
may
require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be
no
assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.
 
 
(c)
Use of Estimates
 
The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.
 
 
(d)
Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.
 
 
(e)
Changes to
Significant Accounting Policies
 
Our significant accounting policies are described in Note
2
of the notes to the financial statements included in our Annual Report on Form
10
-K filed for the year ended
2017.
Apart from the adoption of ASU 
No.
 
2014
-
09,
 Revenue from Contracts with Customers (Topic
606
) on
January 1, 2018
which led to an amended revenue policy, as described in the following paragraphs, there have been
no
changes to those policies.
 
Revenue Recognition
 
Net product revenue
 – We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.
 
Collaboration agreement revenue
 – Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.
 
Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.
 
Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.
 
 
(
f
)
Recently Adopted Accounting Pronouncement
 
In 
May 2014, 
the FASB issued Topic 
606,
which provides comprehensive guidance for revenue recognition. Topic 
606
 affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. 
 
On 
January 
1,
2018,
we adopted Topic 
606
using the cumulative effect adoption method. Results for reporting periods beginning after 
January 
1,
2018
 are presented under Topic 
606
, while prior period amounts are
not
adjusted and continue to be reported in accordance with our historic accounting under Topic
605.
The adoption of Topic
606
did
not
have a material impact on our financial statements.
 
In 
January 2016, 
the FASB issued ASU 
No.
 
2016
-
01
 (ASU 
2016
-
01
), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 
2016
-
01
 changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU 
2016
-
01
 on 
January 1, 2018 
and the adoption did
not
have a material impact on our financial statements.
 
In
May 2017,
the FASB issued ASU
No.
2017
-
09
Compensation – Stock Compensation (Topic
718
) Scope of Modification Accounting (ASU
2017
-
09
). The amendments in ASU
2017
-
09
provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic
718.
We adopted ASU
2017
-
09
effective
January 1, 2018,
and the adoption did
not
have a material impact on our financial statements.
 
 
(
g
)
Recently Issued Accounting Pronouncements
 
In
February 2016,
the FASB issued ASU
No.
2016
-
02
Leases (Topic
842
) (ASU
2016
-
02
), which supersedes existing guidance on accounting for leases in Leases (Topic
840
) and generally requires all leases to be recognized in the consolidated balance sheet. ASU
2016
-
02
is effective for annual and interim reporting periods beginning after
December 15, 2018;
early adoption is permitted. The Company does
not
plan to elect early adoption. The provisions of ASU
2016
-
02
are to be applied using a modified retrospective approach. The Company is currently assessing the future impact of this ASU on its consolidated financial statements.
 
Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did
not
or are
not
believed by management to have a material impact on the Company’s financial statement presentation or disclosures.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Fair Value Measurement
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
(
3
)     Fair Value Measurement
 
The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following
three
 levels:
 
Level 
1
– quoted prices in active markets for identical assets and liabilities
 
Level 
2
– observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are
not
active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
 
Level 
3
– unobservable inputs that are supported by little or
no
market activity and that are significant to the fair value of the assets or liabilities.
 
The following table sets forth the fair value of our financial assets measured on a recurring basis as of
March 31, 2018
and
December 31, 2017
and indicates the fair value hierarchy utilized to determine such fair value (in thousands).
 
   
As of March 31, 2018
 
                                 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                               
Cash and cash equivalents
  $
9,653
    $
    $
    $
9,653
 
 
   
As of December 31, 2017
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                               
Cash and cash equivalents
  $
12,689
    $
    $
    $
12,689
 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Inventories
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Inventory Disclosure [Text Block]
(
4
)
Inventories
 
Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands):
 
   
March 31, 2018
   
December 31, 2017
 
Raw materials
  $
78
    $
70
 
Work in process
   
15
     
92
 
Finished goods
   
55
     
29
 
Total
  $
148
    $
191
 
 
Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts
may
result in recording additional write downs for excess or expired inventory in the future. Charges to cost of goods sold for inventory write-downs, reserve adjustments, scrap, shrinkage and expired inventories totaled approximately
$2,000,
and
$9,000
for the
three
months ended
March 31, 2018
and
2017,
respectively.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Property and Equipment, Net
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]
(
5
)
Property and Equipment, Net
 
Property and equipment, net consisted of the following (in thousands):
  
   
March 31,
2018
   
December 31,
2017
 
Computer equipment and software
  $
110
     
106
 
Laboratory and manufacturing equipment
   
447
     
447
 
Furniture and fixtures
   
48
     
48
 
Leasehold improvements
   
326
     
326
 
Property and equipment, gross
   
931
     
927
 
Less accumulated depreciation
   
(779
)    
(758
)
Property and equipment, net
  $
152
     
169
 
 
Depreciation expense totaled approximately
$22,000
and
$13,000
for the
three
months ended
March 31, 2018
and
2017,
respectively.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 6 - Accrued Expenses and Other Current Liabilities
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Accrued Liabilities and Other Current Liabilities Disclosure [Text Block]
(
6
)
Accrued
Expenses and Other Current
Liabilities
 
Accrued expenses and other current liabilities consisted of the following (in thousands):
  
   
March 31,
2018
   
December 31,
2017
 
Accrued expenses
  $
579
    $
539
 
Grant liability
   
654
     
663
 
Customer deposits
   
90
     
61
 
Total
  $
1,323
    $
1,263
 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
(
7
)
Share-Based Compensation
 
The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function.
No
share-based compensation was capitalized during the periods presented. Share-based compensation expense for the
three
months ended
March 31, 2018
and
2017
was recorded as follows (in thousands):
  
   
Three months ended March 31,
 
   
2018
   
2017
 
Cost of goods sold
  $
30
    $
41
 
Research and development
   
197
     
172
 
Selling, general and administrative
   
388
     
409
 
Share-based compensation expense
  $
615
    $
622
 
 
The following table summarizes the activity of stock options and related information:
 
   
 
 
 
 
Weighted
 
   
 
 
 
 
average
 
   
Number of
   
exercise
 
   
shares
   
price
 
Balance, December 31, 2017
   
4,213,100
    $
2.96
 
Stock options granted
   
1,429,075
     
2.60
 
Stock options exercised
   
(2,488
)    
1.80
 
Stock options cancelled
   
(20,833
)    
7.56
 
Balance, March 31, 2018
   
5,618,854
    $
2.85
 
 
The weighted average grant-date fair value of options granted during the
three
months ended
March 31, 2018
was
$1.86
 per share.
 
Employee Share-Based Compensation (Stock Options)
 
During the
three
months ended
March 31, 2018,
we granted stock options to certain non-employee directors and employees to purchase
1,429,075
shares of common stock. The fair value of each option grant was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:  
 
Risk-free interest rate
   
2.66%
 
Volatility
   
81%
 
Dividend yield
 
None
 
Expected term (in years)
   
6.25%
 
 
Unrecognized share-based compensation for employee options granted through
March 31, 2018
is approximately
$6.7
million to be recognized over a remaining weighted average service period of
3.1
years.
 
Non-Employee Director
Share-Based Compensation (RSUs)
 
The following summarizes the activity of non-vested RSUs:
  
   
 
 
 
 
Weighted
 
   
 
 
 
 
average
 
   
 
 
 
 
grant date
 
   
Number of
   
fair value
 
   
shares
   
per share
 
Balance, December 31, 2017
   
97,996
    $
8.71
 
RSUs granted
   
     
 
 
RSUs vested
   
(20,444
)    
11.04
 
RSUs forfeited
   
     
 
 
Balance, March 31, 2018
   
77,552
    $
8.09
 
 
Unrecognized share-based compensation for employee RSUs granted through
March 31, 2018
is approximately
$441,000
to be recognized over a remaining weighted average service period of
1.7
years.
 
Nonemployee Share-Based Compensation
 
During the
three
months ended
March 31, 2018,
we did
not
grant any options to purchase shares of common stock to consultants. Options granted to consultants have been granted in exchange for consulting services to be rendered and vest over the term specified in the grant, which correlates to the period the services are rendered. We recorded approximately
$45,000
and
$233,000
for the
three
months ended
March 31, 2018
and
2017,
respectively, as nonemployee share-based compensation expense.
 
The Company accounts for share-based compensation arrangements with nonemployees, using the Black-Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, the Company revalues the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards for the
three
months ended
March 31, 2018:
 
Risk-free interest rate
 
 
2.83%
 
Volatility
 
 
80%
 
Dividend yield  
 
None
 
Expected term (in years)
 
 8.4
-
8.8
         
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 8 - Net Loss Per Share
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Earnings Per Share [Text Block]
(
8
)
Net Loss per Share
 
Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is
no
difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to our net loss position.  
 
The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:
 
   
Three months ended March 31,
 
   
2018
   
2017
 
Stock options to purchase common stock
   
5,618,854
     
3,816,927
 
Unvested restricted stock units
   
77,552
     
61,333
 
Total
   
5,696,406
     
3,878,260
 
 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Income Taxes
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
(
9
)     Income Taxes
 
During the
three
months ended
March 31, 2018
and
2017,
there was
no
income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statement of operations due to the Company’s net loss and a full valuation allowance on the resulting deferred tax assets.
 
As of
March 31, 2018,
we retain a full valuation allowance on our deferred tax assets in all jurisdictions. The realization of our deferred tax assets depends primarily on our ability to generate future taxable income which is uncertain. We do
not
believe that our deferred tax assets are realizable on a more-likely-than-
not
basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.
 
On
December 22, 2017,
the Tax Cuts and Jobs Act (H.R.
1
) (the Tax Act) was signed into law. The new law resulted in significant changes to the U.S. corporate income tax system. These changes included the reduction of the corporate income tax rate from a maximum rate of 
35%
to 
21%
and the elimination or reduction of certain domestic deductions and credits.
 
The
2017
provisional charge related to the Tax Act was an estimate and the measurement of net deferred tax assets is subject to further analysis and potential correlative adjustments as developing interpretations and guidance from the U.S. Treasury Department, the Internal Revenue Service, and other standard setting bodies provide additional clarifications of the provisions of the Tax Act. Updated guidance and regulations could result in changes to this provisional charge during
2018
when the analysis is complete, and, in accordance with the guidance in Staff Accounting Bulletin
118,
we will continue to monitor guidance and make necessary adjustments.
No
measurement-period adjustments were made during the quarter ended
March 31, 2018.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 10 - Related Party Transactions
3 Months Ended
Mar. 31, 2018
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]
(
10
)     Related Party Transactions
 
In
August 2016,
we granted an option to purchase
418,977
shares of common stock, with
4
-year vesting period and an exercise price of
$1.80
per share, to OPKO Health, Inc. (“OPKO”) as consideration for consulting services to be provided by OPKO. We recorded
$37,000
and
$122,000
as share-based compensation expense related to the OPKO stock option during the
three
months ended
March 31, 2018
and
2017,
respectively. The estimated grant-date fair value of the option was
$5.3
million. The term of the consulting agreement is
4
years and will be automatically renewed for successive
one
year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than
5%
of the outstanding shares of the Company’s common stock and OPKO itself is also a beneficial owner of more than
5%
of the outstanding shares of the Company’s common stock. 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]
(a)
Basis of Preparation
     
    The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of
March 31, 2018
and for the
three
months ended
March 31, 2018
and
2017
are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information and on a basis consistent with the annual financial statements and, in the opinion of management, reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position as of
March 31, 2018,
results of operations for the
three
months ended
March 31, 2018
and
2017,
and cash flows for the
three
months ended
March 31, 2018
and
2017.
The results for the
three
months ended
March 31, 2018
are
not
necessarily indicative of the results to be expected for the year ending
December 31, 2018
or for any other interim period or for any other future year.
     
    These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form
10
-K for the year ended
December 31, 2017,
filed with the SEC on
March 16, 2018.
Going Concern and Liquidity [Policy Text Block]
(b)
Liquidity
     
    We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of
$76.0
million as of
March 31, 2018.
Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of 
$9.7
million as of
March 31, 2018
are sufficient to fund the Company into the
fourth
quarter of
2018.
These factors raise substantial doubt about our ability to continue as a going concern beyond
one
year from the date these financial statements are issued. The financial statements do
not
include any adjustments that might result from the outcome of this uncertainty.
     
   
Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP cell therapy system, and our
second
therapeutic candidate, the CardiALLO cell therapy system, through and beyond the
fourth
quarter of
2018,
will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are
not
available, we
may
be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that
may
require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be
no
assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.
Use of Estimates, Policy [Policy Text Block]
(c)
Use of Estimates
 
The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.
Consolidation, Policy [Policy Text Block]
(d)
Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.
Revenue from Contract with Customer [Policy Text Block]
(e)
Changes to
Significant Accounting Policies
 
Our significant accounting policies are described in Note
2
of the notes to the financial statements included in our Annual Report on Form
10
-K filed for the year ended
2017.
Apart from the adoption of ASU 
No.
 
2014
-
09,
 Revenue from Contracts with Customers (Topic
606
) on
January 1, 2018
which led to an amended revenue policy, as described in the following paragraphs, there have been
no
changes to those policies.
 
Revenue Recognition
 
Net product revenue
 – We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.
 
Collaboration agreement revenue
 – Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.
 
Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.
 
Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.
New Accounting Pronouncements, Policy [Policy Text Block]
(
f
)
Recently Adopted Accounting Pronouncement
 
In 
May 2014, 
the FASB issued Topic 
606,
which provides comprehensive guidance for revenue recognition. Topic 
606
 affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. 
 
On 
January 
1,
2018,
we adopted Topic 
606
using the cumulative effect adoption method. Results for reporting periods beginning after 
January 
1,
2018
 are presented under Topic 
606
, while prior period amounts are
not
adjusted and continue to be reported in accordance with our historic accounting under Topic
605.
The adoption of Topic
606
did
not
have a material impact on our financial statements.
 
In 
January 2016, 
the FASB issued ASU 
No.
 
2016
-
01
 (ASU 
2016
-
01
), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 
2016
-
01
 changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU 
2016
-
01
 on 
January 1, 2018 
and the adoption did
not
have a material impact on our financial statements.
 
In
May 2017,
the FASB issued ASU
No.
2017
-
09
Compensation – Stock Compensation (Topic
718
) Scope of Modification Accounting (ASU
2017
-
09
). The amendments in ASU
2017
-
09
provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic
718.
We adopted ASU
2017
-
09
effective
January 1, 2018,
and the adoption did
not
have a material impact on our financial statements.
 
 
(
g
)
Recently Issued Accounting Pronouncements
 
In
February 2016,
the FASB issued ASU
No.
2016
-
02
Leases (Topic
842
) (ASU
2016
-
02
), which supersedes existing guidance on accounting for leases in Leases (Topic
840
) and generally requires all leases to be recognized in the consolidated balance sheet. ASU
2016
-
02
is effective for annual and interim reporting periods beginning after
December 15, 2018;
early adoption is permitted. The Company does
not
plan to elect early adoption. The provisions of ASU
2016
-
02
are to be applied using a modified retrospective approach. The Company is currently assessing the future impact of this ASU on its consolidated financial statements.
 
Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did
not
or are
not
believed by management to have a material impact on the Company’s financial statement presentation or disclosures.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Fair Value Measurement (Tables)
3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
   
As of March 31, 2018
 
                                 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                               
Cash and cash equivalents
  $
9,653
    $
    $
    $
9,653
 
   
As of December 31, 2017
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Assets:
                               
Cash and cash equivalents
  $
12,689
    $
    $
    $
12,689
 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Inventories (Tables)
3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   
March 31, 2018
   
December 31, 2017
 
Raw materials
  $
78
    $
70
 
Work in process
   
15
     
92
 
Finished goods
   
55
     
29
 
Total
  $
148
    $
191
 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Property and Equipment, Net (Tables)
3 Months Ended
Mar. 31, 2018
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   
March 31,
2018
   
December 31,
2017
 
Computer equipment and software
  $
110
     
106
 
Laboratory and manufacturing equipment
   
447
     
447
 
Furniture and fixtures
   
48
     
48
 
Leasehold improvements
   
326
     
326
 
Property and equipment, gross
   
931
     
927
 
Less accumulated depreciation
   
(779
)    
(758
)
Property and equipment, net
  $
152
     
169
 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 6 - Accrued Expenses and Other Current Liabilities (Tables)
3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]
   
March 31,
2018
   
December 31,
2017
 
Accrued expenses
  $
579
    $
539
 
Grant liability
   
654
     
663
 
Customer deposits
   
90
     
61
 
Total
  $
1,323
    $
1,263
 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation (Tables)
3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Share-based Compensation, Expense [Table Text Block]
   
Three months ended March 31,
 
   
2018
   
2017
 
Cost of goods sold
  $
30
    $
41
 
Research and development
   
197
     
172
 
Selling, general and administrative
   
388
     
409
 
Share-based compensation expense
  $
615
    $
622
 
Share-based Compensation, Stock Options, Activity [Table Text Block]
   
 
 
 
 
Weighted
 
   
 
 
 
 
average
 
   
Number of
   
exercise
 
   
shares
   
price
 
Balance, December 31, 2017
   
4,213,100
    $
2.96
 
Stock options granted
   
1,429,075
     
2.60
 
Stock options exercised
   
(2,488
)    
1.80
 
Stock options cancelled
   
(20,833
)    
7.56
 
Balance, March 31, 2018
   
5,618,854
    $
2.85
 
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]
   
 
 
 
 
Weighted
 
   
 
 
 
 
average
 
   
 
 
 
 
grant date
 
   
Number of
   
fair value
 
   
shares
   
per share
 
Balance, December 31, 2017
   
97,996
    $
8.71
 
RSUs granted
   
     
 
 
RSUs vested
   
(20,444
)    
11.04
 
RSUs forfeited
   
     
 
 
Balance, March 31, 2018
   
77,552
    $
8.09
 
Non-employee Stock Options [Member]  
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Risk-free interest rate
 
 
2.83%
 
Volatility
 
 
80%
 
Dividend yield  
 
None
 
Expected term (in years)
 
 8.4
-
8.8
         
Employee Stock Option [Member]  
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Risk-free interest rate
   
2.66%
 
Volatility
   
81%
 
Dividend yield
 
None
 
Expected term (in years)
   
6.25%
 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 8 - Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2018
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
Three months ended March 31,
 
   
2018
   
2017
 
Stock options to purchase common stock
   
5,618,854
     
3,816,927
 
Unvested restricted stock units
   
77,552
     
61,333
 
Total
   
5,696,406
     
3,878,260
 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 2 - Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Dec. 31, 2016
Retained Earnings (Accumulated Deficit), Ending Balance $ (75,988) $ (72,450)    
Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 9,653 $ 12,689 $ 19,032 $ 21,352
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Assets:    
Cash and cash equivalents $ 9,653 $ 12,689
Fair Value, Inputs, Level 1 [Member]    
Assets:    
Cash and cash equivalents 9,653 12,689
Fair Value, Inputs, Level 2 [Member]    
Assets:    
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]    
Assets:    
Cash and cash equivalents
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Inventories (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Inventory Write-down $ 2,000 $ 9,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 4 - Inventories - Summary of Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Raw materials $ 78 $ 70
Work in process 15 92
Finished goods 55 29
Total $ 148 $ 191
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Property and Equipment, Net (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Depreciation, Total $ 22,000 $ 13,000
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Property and equipment, gross $ 931 $ 927
Less accumulated depreciation (779) (758)
Property and equipment, net 152 169
Computer Equipment and Software [Member]    
Property and equipment, gross 110 106
Laboratory and Manufacturing Equipment [Member]    
Property and equipment, gross 447 447
Furniture and Fixtures [Member]    
Property and equipment, gross 48 48
Leasehold Improvements [Member]    
Property and equipment, gross $ 326 $ 326
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Accrued expenses $ 579 $ 539
Grant liability 654 663
Customer deposits 90 61
Total $ 1,323 $ 1,263
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation (Details Textual) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 1.86  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,429,075  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 6,700,000  
Allocated Share-based Compensation Expense, Total $ 615,000 $ 622,000
Employee Stock Option [Member]    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 3 years 36 days  
Restricted Stock Units (RSUs) [Member]    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 1 year 255 days  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options $ 441,000  
Non-employee Directors and Employees [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,429,075  
Consultants [Member]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0  
Non-employees [Member]    
Allocated Share-based Compensation Expense, Total $ 45,000 $ 233,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Share-based compensation expense $ 615 $ 622
Cost of Goods Sold [Member]    
Share-based compensation expense 30 41
Research and Development Expense [Member]    
Share-based compensation expense 197 172
Selling, General and Administrative Expenses [Member]    
Share-based compensation expense $ 388 $ 409
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation - Stock Option Activity (Details)
3 Months Ended
Mar. 31, 2018
$ / shares
shares
Stock options outstanding, beginning of period (in shares) | shares 4,213,100
Balance, weighted average exercise price, beginning of period (in dollars per share) | $ / shares $ 2.96
Stock options granted (in shares) | shares 1,429,075
Stock options granted, weighted average exercise price (in dollars per share) | $ / shares $ 2.60
Stock options exercised (in shares) | shares (2,488)
Stock options exercised, weighted average exercise price (in dollars per share) | $ / shares $ 1.80
Stock options cancelled (in shares) | shares (20,833)
Stock options cancelled, weighted average exercise price (in dollars per share) | $ / shares $ 7.56
Stock options outstanding, end of period (in shares) | shares 5,618,854
Balance, weighted average exercise price, end of period (in dollars per share) | $ / shares $ 2.85
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) - Employee Stock Option [Member]
3 Months Ended
Mar. 31, 2018
Risk-free interest rate 2.66%
Volatility 81.00%
Dividend yield 0.00%
Expected term (in years) (Year) 6 years 91 days
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member]
3 Months Ended
Mar. 31, 2018
$ / shares
shares
Balance, Shares (in shares) | shares 97,996
Balance, Weighted average grant date fair value per share (in dollars per share) | $ / shares $ 8.71
RSUs granted, Shares (in shares) | shares
RSUs granted, Weighted average grant date fair value per share (in dollars per share) | $ / shares
RSUs vested, Shares (in shares) | shares (20,444)
RSUs vested, Weighted average grant date fair value per share (in dollars per share) | $ / shares $ 11.04
RSUs forfeited, Shares (in shares) | shares
RSUs forfeited, Weighted average grant date fair value per share (in dollars per share) | $ / shares
Balance, Shares (in shares) | shares 77,552
Balance, Weighted average grant date fair value per share (in dollars per share) | $ / shares $ 8.09
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) - Non-employee Stock Options [Member]
3 Months Ended
Mar. 31, 2018
Risk-free interest rate 2.83%
Volatility 80.00%
Dividend yield 0.00%
Minimum [Member]  
Expected term (in years) (Year) 8 years 146 days
Maximum [Member]  
Expected term (in years) (Year) 8 years 292 days
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Antidilutive securities (in shares) 5,696,406 3,878,260
Employee Stock Option [Member]    
Antidilutive securities (in shares) 5,618,854 3,816,927
Restricted Stock Units (RSUs) [Member]    
Antidilutive securities (in shares) 77,552 61,333
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 9 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Income Tax Expense (Benefit), Total $ 0 $ 0    
Deferred Tax Liabilities, Net, Total $ 0      
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent       35.00%
Scenario, Forecast [Member]        
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent     21.00%  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 10 - Related Party Transactions (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Aug. 31, 2016
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   1,429,075    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance   $ 2.85   $ 2.96
Allocated Share-based Compensation Expense, Total   $ 615,000 $ 622,000  
OPKO [Member]        
Related Party, Ownership Percentage 5.00%      
OPKO [Member] | Consulting Services [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 418,977      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 4 years      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance $ 1.80      
Allocated Share-based Compensation Expense, Total   37,000 $ 122,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value   $ 5,300,000    
Consulting Agreement, Term 4 years      
Consulting Agreement, Term, Length of Automatic Renewal Periods 1 year      
Chairman and Chief Executive Officer of OPKO [Member]        
Related Party, Ownership Percentage 5.00%      
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

C6>R)4W)2ZL49 MWZH\BEU!P*&T+@+#Y0P'X-P%PC+^3#&C.:4C+O=OT;]X[:CEQ P<%/_=5;;- MH_N(5%"S@=LG-7Z%2<^GB$SBO\,9.,)=)9BC5-SX+RD'8Y68HF I@KV&M9-^ M'O[Z@XCMA8B V7J,#%7$<7Q1R#7H80D*I=#%W0K0C6]#0THU2.M4 M++QSIS\F[FTN_'N<@-"P[V'"^/Q@NNFD(2=E\>7]^]1*6< :XSOLR18G=C8X MU-9MM[C7H6^#854_C22=_PO%/U!+ P04 " #8:JI,G!F*@>4! D!0 M&0 'AL+W=O,*!V**Y:] %+9(D9QZ/L?,"-MA_+4YLXB M3_E-T;:#L_#DC3$B_IR \B%# 7HDGMMKHTP"YVE/KO #U,_^+'2$9Y>J9=#) MEG>>@#I#'X-CD1B]%;RT,,C%W#.=7#A_-<'7*D.^ 0(*I3(.1 ]W*(!28Z0Q M?D^>:%[2%"[G#_?/MG?=RX5(*#C]U5:JR= >>174Y$;5,Q^^P-1/@KRI^6]P M!ZKEAD2O47(J[:]7WJ3B;'+1*(R\C6/;V7&8_!]E[H)P*@CG@B#^;T$T%42K M CR2V58_$47R5/#!$^-A]<3 8Z\^#_3[%=V,T:4ZC M)EQHPO>*8JN(_%F"-#>'TJ#LVBG1$$+^ZK>3^^$W%M.^E=N-)7WU[0FG,%VL]_TH:-?K+F@$*M MS'2GYV+\XXZ!XOWT)N'Y8IJ3H0S-RI 22>-$H+9M'4+36#!E9[DN TC>,M%:R749E[WU&7 MN1HM[R4<-3&C$$S_W0-74Q$ET:OCJ6\[ZQRTS ?6P@^P/X>C1HLN4>I>@#2] MDD1#4T2/R>Z0.;P'_.IA,JL]<4I.2CT[XVM=1+$K"#A4UD5@N)SA )R[0%C& MGSEFM*1TQ/7^-?IGKQVUG)B!@^*_^]IV1?0A(C4T;.3V24U?8-9S'Y%9_#XJP1S5(H;_R75:*P2/%A\J\U$_,LC+7:B(Z/-; 7$\DNPPOLW).?W?^#-4:])[+Y&.6T[,+-&/V M 9.N,0N"8O0E17HKQ3Z]HJ?O$QRN$=OM[0S931&9YV_>B=A]-.2D++Z]?Z%&*0M89'R'7=GAS"X&A\:Z[0/N=>C<8%@US$-)ES]#^0]0 M2P,$% @ V&JJ3$ .G=)" @ TP< !D !X;"]W;W)K&ULC97;CILP$(9?!7'?->9,1)!VLZI:J96BK;:]=A(GH#68VD[8 MOGUM0U "DR@W^, _X^^W89QW7'S(DE+E?-:LD4NW5*I=("2W):V)?.(M;?2; M/1:QK(OZ]4,:[ MI8O=\\1;=2B5F4!%WI(#_475>[L6>H3&++NJIHVL>.,(NE^ZSWBQPKX)L(K? M%>WD1=\Q5C:N/=-SH8BEQG\ M!'HSMV;2[IU]I]U*/7LJDUT<4B7Y(D MFY! HBB%44(0)9RA!%.2<+8(CJ9' VCB#.:(0(X(V)(;1F(P0?S X<9S2NQ- MG :+X9!$A D 4!N;$4*)D@?<)+.*,-P M UX&T15H.OWU[VJN46Z4( RXP3=2P/4#/U) \+PZ!'X\M7-?U,.@B^IJKKN? M1!RJ1CH;KG2AMN5TS[FB.J'WI'>FU#?L.&!TKTPWT7W17S/]0/%VN$+1>(\7 M_P%02P,$% @ V&JJ3!?K)4?H 0 *@4 !D !X;"]W;W)K&UL?931CIP@%(9?Q? BXK.="9JTK5IVJ1-)MNTO6;T.)H% ML<",V[L!@FT=B;.6_;/KW?1R MI@I*P7YWM6YS] $%-33TRO2+&+_ W$^*@KGY;W #9N26Q*Q1":;<,ZBN2@L^ M5S$HG+Y-8]>[<9SKWVU^0SP;XL40)?\UD-E 5@8\D;E6/U%-BTR*,9#3QQJH M/1/1D9C-K&S2[9U[9[I5)GLKXC#.\,T6FC7/DR9^U+Q7E%L%"1<)-@ +1>RE MB)T_>4=!5A239N\TO=.D^\.*PZ,A!S\(\8(0#TBR IDTZ<,BNW2E*3V:'?&# M)%Z0Q .2KD"2S2*'<,6QE>PB/T;JQ4@W&-%A?3S2S:9')%Y]O=(CBC<[@A]. MK;U%OE-YZ7H5G(4V/X [IHT0&DS!\,E4;,W%M00,&FVG>S.7T^\[!5H,\\V$ ME^NQ^ =02P,$% @ V&JJ3%R-+P^0 @ 1PD !D !X;"]W;W)K&ULC5;MCILP$'P5Q ,$;#X3$:0D5=5*K11=U?:W0YR M#C"UG7!]^]J&< 26ZO(CV)O9F5V;B9VTC+^*G%)IO55E+;9V+F6S<1R1Y;0B M8L4:6JM?+HQ71*HIOSJBX92<35)5.MAU0Z9JPFRR+FAZY)6Y5 M1?C?/2U9N[61_0B\%-=5<5+06!:LM3B];>X?#UO;5=71$N:24U!U.-.#[0L-9.JXT]/:@^: M.G$\?K!_-LVK9DY$T ,K?Q=GF6_MV+;.]$)NI7QA[1?:-Q385M_]-WJGI8+K M2I1&QDIAOJWL)B2K>A952D7>NF=1FV?;\S_2X 3<)^ A 87_3?#Z!.\]P3?- M=Y695C\12=*$L];BW6XU1+\4:..IQ P1X0AK."!37@FWW]J(IHTT6'6!E-W3:SB!14? M5/$!E7BBTF&"L8J/UVX4P$(!*!0 0NN)4(>)1D)AY.H/+!2"0N%<"+D3H7 N MA(*Q3K>% SCQ7(BL)QH5@Z*,$P0@P0QT ^:] -A%D36H,@:(/!@ N3"GG,_ M4"<(\A=T%KR- (I@JH-F.^?[:''G$.CQ'<* U(*[$&QB!+EXZJ\>]&&#(=C* M"/ RBA8H8),BR*6S8N[T%/;P'@<@"&/6_^ MLCBCXZ>B_&I.:F%E[%9+_4<_B@ZW@1W6Q]W!'.LO=-T5XSOA%^+6E@G M)M7A:(ZP"V.2JC+=E5KP7-UJADE)+U(/(S7FW='>321K^FN+,]R=TG]02P,$ M% @ V&JJ3.WE'+,F @ ?08 !D !X;"]W;W)K&ULC57MCILP$'P5Q .T$1N_E+)=(R2*$FHBGE@+C7IR8KPF M4H7\C$3+@1Q-44T1#H(EJDG5^'EF9^PB:=7 GGOB4M>$_]D"9=W&#_U; MXJ4ZEU(G4)ZUY P_0/YL]UQ%:& Y5C4THF*-Q^&T\9_#]2[5> -XK: 3H[VG MG1P8>]/!U^/&#[0@H%!(S4#4C\+W^O-?X,K4 772E2/@E%A?KWB(B2K>Q8E MI2;O=JT:LW8]_ZW,78#[ CP4J-[_*XCZ@NBC(#;FK3)C]1.1),\XZSQN_ZR6 MZ'8<(!@13[T *[6FSQK!S_ MVV W1RR7[@Z1TT1DZN-Q!QQ,3%A,8C"-[1$N)CH<&(S=0F*GD-@AY,Y9+9P$ MBP><6,QBI#*:0'9S2'Q'QM(I8^F0<><@$B=!\H"/9"8R3).)$0V^BU6KB9(Z)@W0B!(UN;0W\; :<\ IV::2^'Z/L,$.? ML;[UD_Q6S58["C]H[&#^3OBY:H1W8%+-%'/S3XQ)4!*#)W7.I?H6# &%D]3; M1.VYG8@VD*SMAST:OCCY7U!+ P04 " #8:JI,&$DOLTX" ^!P &0 M 'AL+W=O_P9ZLY^)-EHPIY[VI6[ES M2Z6Z+4*R*%E#Y89WK-5O+EPT5.FEN"+9"4;/-JBI$?&\"#6T:MT\L[:CR#-^ M4W75LJ-PY*UIJ/AS8#7O=RYV'X;7ZEHJ8T!YUM$K^\[4C^XH] I-6OET]PQ4DZF"7R>/[)_LN*UF!.5[(77OZJS*G=NXCIG=J&W6KWR_C,;!86N M,ZK_RNZLUNZF$LTH>"WMTREN4O%FS*)+:>C[,%:M'?LQ_R,,#B!C )D"?!N M!I"M_"-5-,\$[QTQ;'Y'S3?&6Z+WIC!&NQ7VG2Y>:NL])R3(T-TD>.@P]Y M\L&3!]+9)P2!$ >R""J/E @B2!,0F(20 ,GF&2A1:\68&D("0%(&0&20$M7N+[, =[\*GS M )(_/W;>0D^\"5<^#EXYWA@ +ALWRCXEJUTCEQI2]1>]5=.%=, M%^-MM.12-[-I4;.+,M-8S\5PHP\+Q;NQ6Z&I9>9_ 5!+ P04 " #8:JI, MV;0'_M4! # ! &0 'AL+W=OT+V'%=E_X)['IV M9I:P9*-4;[H%,.A=\%[GN#5F.!"BRQ8$TW=R@-Y^J:42S-A0-40/"ECEBP0G M-(I2(EC7XR+SN9,J,GDQO.OAI)"^",'4KR-P.>8XQK?$:]>TQB5(D0VL@:]@ MO@TG92.RL%2=@%YWLD<*ZAP_QH=CZO >\+V#4:_VR'5REO+-!9^J'$?.$' H MC6-@=KG"$W#NB*R-GS,G7B1=X7I_8W_QO=M>SDS#D^0_NLJT.7[ J(*:7;AY ME>-'F/O98S0W_QFNP"W<.;$:I>3:_Z+RHHT4,XNU(MC[M':]7\>9_U86+J!S M 5T*8G\X9!+RSI^9846FY(C4=/8#>G] MW*ZRRW@^4G\#_\"GV?["5-/U&IVEL??8W[9:2@/62G1G&V[M<[($'&KCMO=V MKZ:AF@(CA_F](,NC5?P&4$L#!!0 ( -AJJDSLC*,51@( #X' 9 M>&PO=V]R:W-H965T*UJ+ MG5M(V6P1$GD!%1$KUD"MOIP9KXA42WY!HN% 3L:HH@A[W@95I*S=+#5[SSQ+ MV572LH9G[HAK51'^]P"4M3O7=^\;+^6ED'H#96E#+O 3Y&OSS-4*#5Y.906U M*%GM<#COW+V_/?A8&QC%KQ):,9H[.I4C8V]Z\>VTU)Q_.F=N@-3&X[G=^]?3/(JF2,1\,3H[_(DBYT;N\X)SN1*Y0MKOT*?4.@Z M??;?X094R74DBI$S*LR_DU^%9%7O1852D?=N+&LSMKW_NYG= /<&>#!8&P/4 M@4SDGXDD6"%VKUE. A3=-..>LVAT^"1 MQA\42'D?$-B&.."9.<:AW<':&N/:. @>8MQ,8NPTH='41I-$2;*Q8P(K)K!@ MH@FFTR0C3+R*?&_T6SB:T(H,+?<.+9%?G^REO )%9,8L'@"6:N63HRW[-7GF>A MK*>E-Q5$43C*^9%DK?.]CS]00+WHL8*\:4IH]'Q5P"_F MX19.SJZUZ1JCW:$Y[$UO0/_E76?Y0?BEK(5S9%(]HN:I.S,F007CK53"A6IF MPX+"6>III.:\>]&[A61-WZW0T#*S?U!+ P04 " #8:JI,P\<%/O4! "G M!0 &0 'AL+W=OWJ![Z!_]$=I(K*P MU"V'3K6B\R2<"_\QV!\RBW> GRV,:K7W;";T%TE;N-[?V)]=[Z:7$U7P)-BOMM9-X>]\KX8S'9A^$>-GF/N) M?6]N_BM<@1FX=6(T*L&4^WK5H+3@,XNQPNG[M+:=6\>9_U:&%X1S0;@4!*GK M91)RSC]13RS"./D6=;AUY=&Z?)O>.40P<8R+1*A(A(AD=R(()DYP MD1@5B3\21,&="(;YQW4EJ$B"N$QQ@A0E2!$'VSN7"";>X2([5&2'$&0X0882 M9/_A$L$DFSL1LGHH'.3%C0CE56+HW'A:99VDYY)Z'- M3K-C"K3HY[%(EME<_@%02P,$% M @ V&JJ3$$0C\0: @ R04 !D !X;"]W;W)K&ULC531CILP$/P5Q >8N]Z=G:&V)L/7+S(&D!YKRWK9.'72O4;A&150TOE ^^ATR78M-#)AG>>@%/A/X6;76KP%O"K@4'>[3WCY,#Y MBPF^'@L_,(* 0:4, ]7+%7; F"'2,OY,G/[[]_8/UOOVLN!2MAQ]KLY MJKKP,]\[PHE>F'KFPQ>8_"2^-YG_!E=@&FZ4Z!X59]+^>M5%*MY.+%I*2U_' MM>GL.HPG:3R5N0OP5(#G MW[?P715!#="FP'-"JS5C]11.%KCHBPDCSAU"R).060M*(SDZ-8^5&,PZY M[U2-#Z:CU7YX#!29EMJO=BG"YCH'@_#4XT3^_R M'U!+ P04 " #8:JI,@P7Y<"<" !P!@ &0 'AL+W=OV.VR 0?!7+#W#XV]?(L71)KFJE5HJN:ON;.)O8.C N MD/CZ]@5,G,2AN?MC8#TS.XMA7?2,OXH:0'IOE+1B[M=2=C.$1%4#Q>*!=="J M-SO&*99JR?=(=!SPUI H05$09(CBIO7+PL36O"S809*FA37WQ(%2S/\N@+!^ M[H?^*?#2[&NI Z@L.KR''R!_=FNN5FA4V3846M&PUN.PF_M/X>PYUW@#^-5 M+R[FGJYDP]BK7GS=SOU &P("E=0*6 U'6 (A6DC9^&,U_3&E)E[.3^J?3>VJ ME@T6L&3D=[.5]=Q_]+TM[/"!R!?6?P%;3^I[MOAO< 2BX-J)RE$Q(LS3JPY" M,FI5E!6*WX:Q:DD M QIJ-YNYPA*7!6>]QX?CT&%]ZL)9JCY7I8/FZYAW:C^%BA[+*(L+=-1"%K,8 M,-$%)KQ&K&X149:,&*08YYO,7'@-AH[ M]RLV_.0JQ\3'8L#D!M,:3# IYA[BRD3B-)$X3.03$\E'4Z3.%*DCQ>-D+UV8 M3^XDF3-)=BN0_\=E[A3(WW>YI?P*G9HI3X)%]&Q/3Y% M^KI-XHMPM@P=\95JIT/W.\L/O?@[YONF%=Z&277)S57<,29!60\>U [7JOV/ M"P([J:>YFO.A"0X+R3K;W]'XDRG_ 5!+ P04 " #8:JI,\%Z^6L%K_<^"BHDHOQ3&0C6!TWQI594 02H** M%K6_6K1[#V*UX&=5%C5[$)X\5Q45_]:LY->EC_W7C%)F(U@M&GID/YGZ MU3P(O0HZ+_NB8K4L>.T)=ECZ=WA^CU-CT")^%^PJ>^^>">6)\V>S^+9?^L@H M8B7;*>."ZL>%;5A9&D]:QU_GU.\XC6'__=7[ES9X'W:@YU(]\NM7Y@**?<]%_YU=6*GA1HGFV/%2MK_>[BP5KYP7+:6B+_99U.WS MZOR_FL$&Q!F0SD!SOV<0.H/PLP:1,XC>#*)W#6)G$ \, AM[F\PM572U$/SJ M"5L/#35EA^>Q_EP[L]E^G?8_G4^I=R\KDI)%<#&.'&9M,>0&$]YB-F,,[A"! M5M#)()",-0$HH@$%@+E%;,>()+F%W(\A(8*%AF"^PM8^ZHM V4"HQ<0MIK:Y MB$B.TA@FBD"B:$S4FX7AVL7[#XG8+%<-/ 0-?(R%!1.***0X2FN>"^@8'&D87#+$.@ MJ:\)-P4,=(4L&O) H(DVB.'3CH'CGDT<=PR?=_R9 P^"AH47]*[5BHEC.^-( M;\?/M3*W2F^WFZ/NB+F6!_L;/-_::>C-C1W.?E!Q+&KI/7&E+_WV:CYPKIC6 MB&8ZG2<]#W:+DAV4>4WUN[!#D5THWKB!+^BFSM5_4$L#!!0 ( -AJJDR- M>ED["1D &!Z 4 >&POESVT:6_SS[ M5W1EE5VI"J)YDW(RKI)E*^4='QK+3FHJM1\@H$EB# (<'):9VC]^?^]U V@< M39&TQYG=N"H*8:*/U^^^ /Z8IIGXM ZC],_?K;)L\_C1H]1;R;6;]N*-C'!G M$2=K-\,_D^6C=)-(UT]74F;K\-&PWY\^6KM!])W(H^ ?N;R*\RC[\W?#^>R[ M)S^FP9,?LR?/8B]?RR@3EY$OGD=9D&W%BTBM&<21.!?IRDUD^N.C[,F/CVB. MFC<2K^(H6Z68XTN_>?>5F_3$:."(87\P;]_GP^& MYZ.!!;CK()2)N,*\99RT(+OT/(G[N.NKD;8C:GC>RDV<9'R6S,WR%GG_UJ:X M7N'G. 03N8F&J#7L=6R9^(L,P_,/47P?B5OIIG$$4%^D:6Z'-5ZO0?W;+/8^ M..*6V5"\R;,TX\L_+1N^VFA>A!__ROU@DW,@EBWTJD@K/_[4]_ MVLF_)L&O\64+3\V1>M_.L7]M,<4EIOIJ>N@NFW<7;IBV(+^*P=91"JSC*HW# MP&=N>>J&;N1)X!=*(Q6G!8=H>-Y';NX'&'@&5?#^]IDX/3D3)P*8?[>*\Q24 M:)],>J7PSVP"X:8IMGOE%DJ$NE)#+H+ MI2,BF8EX(=PPC._Y4- APH_SNVR1A\(MIF#(R52XF0 QO56IIWA? "_7=Y"T MX@ .=D@WTLN"CS)LR=V+Z".@ZQ#(FT1NW, 7\M.&D-Z"_UV<@>A>#1OM-:#B M$T@" 4:XV!#%^9C-H6^R%6#N7D9MU7VO($<8N'=!&&2!;-.D1/7&W1*>.^XG MN:R.RN#&#)#77K[-+0N)03[0#%3FK=7KB-IOH:B%'[7*CMFL959QZ$.E_<>_ MSX>#V0^,\FS;P@=(JW=*E6HZZ??Z_0'0DPAP:PY&'$ZIQO7DW_^#JY *I./\KLGHJT* M6+-:P1\HV+OA/P"ZFNC\($9S9S@>X&_,P^F?@[DSG?:_&#IV"^NE#TT&AP*< M0+)Y#B7FN9L G-'!TODZ#UE!^G(1>(&%HU(KVSS(@7R"_>=_MOH^O7'ISDIF M >Q-NK\^O]RM3A\4CY*QV&#[<1BZ"90)R,9D;]GNU@)M%MQA^6VS-6\=,3/> MS^6H"]6AAZ[//NC$G5,?/F[GM+W/VLF,Y$M*LE$LL&\VY)!"WL"61[@19@S1 M*F/1TLU*RBRFY"I.,R5VA:EJ^Q\80K OX]A/!4[6"FW>0JNR)J)U?&P4 MQFR66P8%[BZPZ(BEC"1%%33>]==!Q($*:2B+J6M!V3+V"K$@41BG[;ML>8/( MB]=@/KW&6>ND+Z),@K29'MF]BI[=Z7(H:./.W3HGO(9WU@5P\7TE'8ZX<]/ M4R@.PCS3G/RP&/TB@^4*P\_=C\#14A9\G1.ODKZ/UYN<41?MO:M57<1^[F7B MUU=L@UJ1Z14!>Q_[?\S13 M6V8Q.=AQY"'6JU"&;^F:??0"L_$^2S^3\$J\0*&$!6)-8>AO_$5+@@COYZ ) M-B"Z 3F=XZY6;K0DE5<#@MU=WF,OW[8*(VSN[0[G\?4^R.@*'=*'$':30]4 M T3[364ZB&#>'X(DB3TIH1072;P6D'HH!YEX@8+-,XP) M3L]:WXHE'.1CX /$NZU8=.S=-=&77B()$>RT[1DD6J-)"O[NY#*((MJ9<,ON MTD'S)7FIMIFW^683LMA"1_J(\"$W><*HBB!-M%R+,NU(HQEYL2PN(W8(R!0K-QPKFAJ(&0-TE:+0*"[]F M&!RMTDZME%NQ_#.9>DFP*46^2KN@VPE\ VVR*,U M1(#7!LXC$L.>>),G(I2N;ZZ(Q>"[D>$@4!EV6OWRU8WPX(_HH5N1;E.030=: M,'^DXGV!$Z]@-S$*M@K8'8I1)R,-B9$"\"$"(\JX:C:E,][ ;GE=X?7NX4>1 M?_@0$$QPDQ7@E"M.> ?,4/S"-*(I7FE\/=/XWNGHBC/J*;SDFC&.*P>W5!(+ MMLV=$:M":^-+#I/KWSGVD3MN];IO17'6"I/G=/Y4V@Z]**7;.&X*ER($0HC? M7>U*17_/(X_QR;Q*[*8]DNXU"$F)5%%UQ+H$?F.8^\I8&9*F(^%47$91CC54 MMEI@H^LX68M!OROR5P^+T[DR\#* 1?95]5KR-'7..\0IG1@?BD5PJ M"3:HR);.(#)4!7B!!(8N*HVVD^[0!GD" M/*H!,90($8_$7#D>6U*]P#IX'&&E2ZIH&6OF]62B8#&'+&@YX,B(4IAM=RH. MYT&UX33UA@&WPS"OW2W_1;$X]<[$>V6=GL/:K5TB.XG?QA!'W*1-.YDF8,3& MB<^"R(SVOG?;$S]=7MZ FT!?\N_7;@1=S"<$!M;N!Q 2OI*+V;+=>%+TCL5G&EE9EK*H0YN@<]E.4<@J9YB&$>BXT?8)=$ M$!@)U@FWA1<5 S4E@+V:0@NHWB72_.[O#%^,2S"+_31:EE2XTN$V*\+"-:3D M30A63^U.I5/ET%-+$IVS5_"&"%U9GF@=&!3Y<$Y^\+Z01$0H-PG@"S:AVK6* M< IM?(@N*DZ::2U>)/4-#:* P=?W*X1AV_/XGLI-0&8*=0"/ 70"7P<4 Q>6 MNG8R*B6FKJRC-1Q"8@WT/& MB@0]-<:XU9A-,0:4A323!W.GV%/;8VA$90->QSVZ&HO^A2.F_:GX+Q<:%.2H M[('0N1-\LC/)0).+O=$!KB'H ZY8!;%+.5Y]!:OJE]RO)MB%+XE S&*VJ M&0;&._ X/:50K!-N0 \C$G%GO.9\ BM4ED4FFP2P*?'T5(39OEV@$ZXD M1M"W^VZK++2B):U=D)J)NNL E8B0LDD7@?0A8I;A1/V"A"1)!9C*WK+):D#I M&E@F4(*L""+)"M[!_UX$68N+9*#6BE@34.&9*!XO)7_-Y%*[05G#A!%?*I.0 M*"\G@)YV/[I!R+%7EN M@6NM;AO[@^9K,Y]"&ISP4&RBB.E_5$=K0O6(ASDC#@2*@S*4?;VB8J7>3.,*U)W6[B:"V%%*=K#>5\GP3-?5GMU*E M[\COF?8GO?(?+ZK)&(05M6Z>BO[ ^ME6UR9LLW*1&12\F!7Q ZZ-[ZH!+>!I MN5.Q-%'S0A4*;)A):?MK>9=T'F0HYN.A<=TOKTL'?3!1F__ FQ>WWVBY\V3# MTM7WUE6,NRU3_/KR]JFCK3\-)JE^#JY:TC_X'' MW?0#10FL)"/V<<&3\+I@ M4W$4:)HLSYCWKN#V!"Q6-SF$S2M0X-+&\(497OQUAL CA,#7;I"(G[G&\PHA M>Y[(KM2+,>I9F0>'FN<2&562>:YO\$ROE _2DL5J=.M-NPDVPEXS_"RH%BR M>U)<:S?Y0,Z("^K 871UMHT675=8%ISC.)6? FWSSGJ,G>)LBSA4@;B)KU4 MEP$1UU;A O/B!#KG-YD6KC&!&T2;/*LJ!J4?*S+IK;B-CK28UJEJ'Z5+*?I^ M2:&6&.C/(?.0NAZ1Z_6N/H4-!>>IH?BJUG.I>G:$/2UZ(BZS!TIO,+R^;Z9J/)5.O@II*@H_*6(VA>(U]:M=D]CC&\0MV M!Y7<0#[%THFLY:.\5BF8/%HS0M-QA/:,,@H-EP1LR)R+ MJ;YQH=CN.<6L\>\5U7XH)RO-PK!=)_!;"2E,Z>!3QN8= M+#TF=0H&I>X>$:PI7M%>S6@XY3_;D9<)%5DO1@.(#NE%*FK4FEO;1:S'[9:)RR+O"Y?#H%&@\#61S6 /D%N+FUX8F8 MS,CP3487XB?N@J].QZV5*C MI1#H5%9B-0'<8-C9_^/HY-I\5U4KSQ=7T]2:,MU+^9VKT,(J%KK!09F]' M >D=WUFK)S(D/9'1.:S=W01ZCR#=8CP0ML8F6.:9&,R&8H^.)C&:0_$A\K3U M;I28/@'K3>C_PV&W5\R5W=(W+TKD!'VMR:!65 JJAT8>BZ(5J/2+7NPT<,9#&.H9W)O> MM-\85&SJB].A,YZ3NA[TYLU1'H$0ACRJ[\Q'(PR;]2;3"KH&82?.%)']'$). MH,TGC,W[YMD9PG,.FAH!1N,(1EJ[D]U. /,44;=B5KNXG:ICO5'+GXEGN]=U M#-R]#=(/YPL:$Q0]:I1@(YQ.OZ?G3[ #:[;YX'MH>\H"@@>V@00[OZ:RV7-. M!)-?)9,UZ]0M.!M 3'O#R??B?62DJZTJ@?W/XIA-+.$(<;YW[P%>70YV2$"$Y:EY!.O0S Y>9T!5D%RQO4'Y@O&+ MWK==S'\Q,,2#T5XQ5]JB(AOQV,*=0:#7G^L[@&;"QF84VS\ M/)LY$_@IM!OTR!&TJ@%H(]1X/&!_9@""$<\\R,\/\B]%^B?CB?*6AJ.'W*5: MMJ(L/=%!K*=TDX3B#64?.=,259##CE:1X-/0]3ZBZ5,!]5NO8 MEZ%3-SX&9Z@L,#=:50DE(FV/$V0)9=Y"A C4 >7B6$GY))E1/=;G2B2OJ=,K M$820JG \OJKZVL^KTW>JE,J%[C+@,@"NEY^"CN2PM6L#'GE2E#6H6U[MIFQ) M6:I2^>B(:Q6]AHR:]5<$ZU)EC1#.*=!8;A%?^&G9KM7%$8]WJ+SYJ*[R^@>J MO'F/DAOSWKS;HYOC)D5?+RGBN)%:1[4>R /A<%QCQ%'^&9F\^;S;]1J7**_H2V]WM9?\4;BWM[!K-/3L4% MIQ:K-1\R6-H*@1^Z$L%.4?R@$ECI$0R'1:_50(S@2 WA?Q$W,;)YT0%-1:32 MZ';J;D?M PU%*'CC4M;BG=%UT7[NPC9R?R1AR[,=6U*IZS)?(D[6A:XQCG,Q M@_O/;B_L^FBFLR$Z+;(#LR>3W@@323D#59/O#^V(/"VN6@\>=/9/7MZE7%-N MG;KL?ZRF.6K>5ORJ/P_7Y=\:*_^PC95-!ON)>Q"OC![$JNOR> ;[UKSY^S=O M-BG=[./\ GKD6W?H'[T[M.,QN*J9\@MPV!^R]]3RN*SBJZM:PV)9%C@>Q=_Z M7+_UN7[K<_W6Y_JMS_5K][FVGY2]MW=R?@%C^JVK]EM7[>_252M.WY&V:2=# MU#/)ZF8KQ>*MI)^KQM5J64?W$NI0M>K+>&6T5;XMFRI5FN-7WN%PB?G696GM MLK22U"1;V7KIE)TWQY+B]VEI/*8OSXJ9W0UZGX^8;RUSMI:Y+]3=MA?/'][R M]H4I_Z_87K87YFR3G8(\1V/J_W:#U:XWZ]3Q5.O:(4[032?'XNV/VH2UBTM? MQT5Q\6U57%0 O.?BXI?'^O^7=J"VVHC.J]X=DW>MK]FRZ0O=>2HNJ5^C)0@_ MET\!71I)U6/I\WNT>SSO0I,-2P?#_64Z\PYH4=G/DAI= ]"N<.F5O7Q>:V6X MJK[_D1I\]DY@;PEPDYN1L>]YKH:3MA39D8\JL*:IR: M[V1]IBIT9PZ]IUM%::P^K"_PXHOG51S#_6M7;I)P>E/'A;O7>BA"K=T@YE-1 MYJO:PWK-N+) WUEMNF,N#%BK686\[O_RUN[W;)M[O> ''ITR-+1I3ONZ/0O,)(4<]M$?C:^+81 M!K^JA<%&F&X3E5I8?%V$Q=;=RD#YA1DH[Q2J(P+6&@4/#78/)FHS\FSUFM2# MSQ;EFC'H$6'F_D)B7>.R:M2F).L.+[/T+_E@7#50+^YV*A_^4OOPZNSTFQ2& MI?BZ,/W4)5N58ZEK,_;HLHI\>*_4J<,(ZL ?S(J"[6^RZ8>WV$55!RE\LIW[ M>?$&XTXE]N5@Y\B_ZP#Z1>Q4A#4*T4U 1LH1%J,IHK1M1_-C9Z"HGQNQR?R M%Q7#R:1ST7\RX8S%U"2M*;*5&]D(6HOGBN=FE)HIH+6K.&KLR$-5:;"KP6J# M!Y3E3C6QXU:1:CI<^SV4TVD?6&6;?N)LTRW9 MN):KFG9T;NJ4R,V<+E(B?U MDY&3NJSGI$IS\%GX-,/2,@-2(K&Y9.T7ID[$(YW"Z/ZQJGJ 9;2\.UUO 39? M^BW^Q_+[5V6^HO6H79G7TBT,MAW:+S/'9M5)=I^AR+CL VKGS /OV%.;:]]H%P[R/OW1DU,I.=F:JZ-WE0 M,NN))6W5',99K.:755*K>6<^Z/7[K?'UK%?S;K]KBC4I=DJ_'M;2?%/M*EP, M.JWZ7KJV:NS+61KZX2U4=PIYFR/@C*^L2O M!JHBS^&0%O.^&J!E5O]P6(VI7P/4)3CUWU(QG?KB M%7RO=;ZV+C77"F(P[@XF7KF?]IH_O!C:-8PE*W_..??SKJ2[B:!NJM32]:DQ MT_XC+)W/TWU&4GHPW/F[IF;.NO7;C\9C>V4,\%2U$9Y9XL_R-^MHDI$ZX:28 M+6;E1Q((1<:&;TDZWNI?:BGR=FXFKJ7/7CO_RB>GIAJ3.$#U.MY;.)IT\=XM MAKIP"QSJ!N,75MDYNM,^[O/HWR%)F,%.>EWF2WN-X4OF2MZ8OEDK=?.\<+!N ME(.UN]#PYN8O;W8$<@;6L.\]HK)T%6P*,F*[YI1.0M8V@:[4P3/_(FS1O&Z- M"3\?V77#"25O^<$*87;MO](JG]$2VK) M7HA+B"2]KL:#,$3ROOP5V+9:8E2T-ED!TK6KGAV[6@5R09SF*?WY9K$ $;G0 M;V&H1VF:/?E?4$L#!!0 ( -AJJDRJ/E$0.@( '\* - >&POB27"E=?TF")JL DZ: M"UF#,)%"*DZT<549-+4"DC']^=8B?N< Y1I[C?9[@:/D2![]/>A&&/R:V MP0/RQ1^2_XS[@'IIJ8-^@]*XD&)_GRQ@:A,.:$-8@J\)HVM%;59!.&5;#\\M MD$DF%=+F@(RVR"+-@P]'WK-GU_-P*J1RM7T%_UWWTP\"@V<%4L9&@7/L@32N MB=:@Q(UQW&0'?A="O;W:UD9AJ<@VFB_PE. &4V0M50YJ+!/A 4IC!H65HVA9 MV5'+.K!!K24W1DY)*05Q&H:,WC"T&3!V9R_VYV*/NRN0GV./),3(JAA,L^K> MG$XM=))WV3SW+FUX%"^JZ4;J=ZU9CG"^O3MPJZ"@G?.[8A1@V$E=L^U;1DO! MP2_FEP6C(PNF,1GJH$HJ^F#X[%7)# *HPTH3;-=Y*LB]0HZ/5RGKCA6\_P$ M-?_K?2Y!@")L5[2Y^T]YE_^SXLM7?R_9_54.!3^M77ULB;:3GH#(Q2F(7#ZR MR*!O.CN=;:^OC2A:MY1I*GJY%QT[.7YU_7CKWS-ZJTH9IMJ[KS5FO%_*UKE3XYC;:PI&5\Y6J8=,_]<+& M:U6$M=9U5?9$OS_J5J.4TZV?0 MKH<:MIWNEENB,_\_3&ZU,KF^=GE3:5MOH;PN56V<#6NS"1FSJM+3;->$?;<% MN[&UJ?^PF=UV!6TSUEYZ5DPS#NNUJN&<%Q/,LM09\V<&#OA9P2/XX2"OG"VT M#;I@L!9<:0K@*-BE*I7--4.0@H 4QX24"%(2D/(HD \1!TY%D ,")H"4 /E#&<\>5=EH]E.KT/CX2M8(8TS2- =638MY&BMFK;P^6:IM#%61%5IC3,HU_,"R:3''@'D'%[AU M$#ES[;?,&)$R#3^P:EK$25LQN:LT6ZBW#R7#*

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end
XML 51 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 57 141 1 false 27 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.biocardia.com/20180331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.biocardia.com/20180331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.biocardia.com/20180331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.biocardia.com/20180331/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.biocardia.com/20180331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Summary of Business and Basis of Presentation Sheet http://www.biocardia.com/20180331/role/statement-note-1-summary-of-business-and-basis-of-presentation Note 1 - Summary of Business and Basis of Presentation Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Significant Accounting Policies Sheet http://www.biocardia.com/20180331/role/statement-note-2-significant-accounting-policies Note 2 - Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Fair Value Measurement Sheet http://www.biocardia.com/20180331/role/statement-note-3-fair-value-measurement Note 3 - Fair Value Measurement Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Inventories Sheet http://www.biocardia.com/20180331/role/statement-note-4-inventories Note 4 - Inventories Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Property and Equipment, Net Sheet http://www.biocardia.com/20180331/role/statement-note-5-property-and-equipment-net Note 5 - Property and Equipment, Net Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities Sheet http://www.biocardia.com/20180331/role/statement-note-6-accrued-expenses-and-other-current-liabilities Note 6 - Accrued Expenses and Other Current Liabilities Notes 11 false false R12.htm 011 - Disclosure - Note 7 - Share-based Compensation Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation Note 7 - Share-based Compensation Notes 12 false false R13.htm 012 - Document - Note 8 - Net Loss Per Share Sheet http://www.biocardia.com/20180331/role/statement-note-8-net-loss-per-share Note 8 - Net Loss Per Share Uncategorized 13 false false R14.htm 013 - Disclosure - Note 9 - Income Taxes Sheet http://www.biocardia.com/20180331/role/statement-note-9-income-taxes- Note 9 - Income Taxes Uncategorized 14 false false R15.htm 014 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.biocardia.com/20180331/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Uncategorized 15 false false R16.htm 015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.biocardia.com/20180331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 16 false false R17.htm 016 - Disclosure - Note 3 - Fair Value Measurement (Tables) Sheet http://www.biocardia.com/20180331/role/statement-note-3-fair-value-measurement-tables Note 3 - Fair Value Measurement (Tables) Uncategorized 17 false false R18.htm 017 - Disclosure - Note 4 - Inventories (Tables) Sheet http://www.biocardia.com/20180331/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Uncategorized 18 false false R19.htm 018 - Disclosure - Note 5 - Property and Equipment, Net (Tables) Sheet http://www.biocardia.com/20180331/role/statement-note-5-property-and-equipment-net-tables Note 5 - Property and Equipment, Net (Tables) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.biocardia.com/20180331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables Note 6 - Accrued Expenses and Other Current Liabilities (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 7 - Share-based Compensation (Tables) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-tables Note 7 - Share-based Compensation (Tables) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 8 - Net Loss Per Share (Tables) Sheet http://www.biocardia.com/20180331/role/statement-note-8-net-loss-per-share-tables Note 8 - Net Loss Per Share (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) Sheet http://www.biocardia.com/20180331/role/statement-note-2-significant-accounting-policies-details-textual Note 2 - Significant Accounting Policies (Details Textual) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-3-fair-value-measurement-fair-value-of-assets-measured-on-a-recurring-basis-details Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 4 - Inventories (Details Textual) Sheet http://www.biocardia.com/20180331/role/statement-note-4-inventories-details-textual Note 4 - Inventories (Details Textual) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-4-inventories-summary-of-inventories-details Note 4 - Inventories - Summary of Inventories (Details) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual) Sheet http://www.biocardia.com/20180331/role/statement-note-5-property-and-equipment-net-details-textual Note 5 - Property and Equipment, Net (Details Textual) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-5-property-and-equipment-net-summary-of-property-and-equipment-net-details Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-and-other-current-liabilities-details Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 7 - Share-based Compensation (Details Textual) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-details-textual Note 7 - Share-based Compensation (Details Textual) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-sharebased-compensation-expense-details Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 7 - Share-based Compensation - Stock Option Activity (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-stock-option-activity-details Note 7 - Share-based Compensation - Stock Option Activity (Details) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-valuation-assumptions-for-employee-stock-options-details Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-summary-of-nonvested-rsus-details Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-7-sharebased-compensation-nonemployee-stock-option-valuation-assumptions-details Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) Sheet http://www.biocardia.com/20180331/role/statement-note-8-net-loss-per-share-antidilutive-securities-details Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 9 - Income Taxes (Details Textual) Sheet http://www.biocardia.com/20180331/role/statement-note-9-income-taxes-details-textual Note 9 - Income Taxes (Details Textual) Uncategorized 37 false false R38.htm 037 - Disclosure - Note 10 - Related Party Transactions (Details Textual) Sheet http://www.biocardia.com/20180331/role/statement-note-10-related-party-transactions-details-textual Note 10 - Related Party Transactions (Details Textual) Uncategorized 38 false false All Reports Book All Reports bcda-20180331.xml bcda-20180331.xsd bcda-20180331_cal.xml bcda-20180331_def.xml bcda-20180331_lab.xml bcda-20180331_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 56 0001437749-18-009379-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-18-009379-xbrl.zip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end